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móveis 
 
resumo Atualmente, a resistência a antibióticos constitui uma grande ameaça para a 
saúde pública, reconhecida globalmente. O uso excessivo e incorreto de 
antibióticos é considerado um problema sério que contribui para o aparecimento 
de bactérias resistentes responsáveis pelo aumento da taxa de mortalidade de 
pacientes infetados. Para além disso, a contaminação ambiental com estes 
compostos é também considerada um factor potenciador do aumento da 
prevalência de resistência a antibióticos.  
O objetivo deste estudo foi analisar o perfil de resistência e avaliar a co-seleção 
para características de resistência a antibióticos e metais em isolados 
ambientais de Pseudomonas e Chromobacterium utilizando uma estratégia de 
sequenciação dos genomas. Para isso, os genomas dos isolados foram 
sequenciados e a identificação destes foi confirmada através de uma análise 
filogenética baseada na sequencia de marcadores moleculares. As 
características fenotípicas obtidas foram consistentes com a afiliação P. 
aeruginosa e C. haemolyticum. A análise do genoma efectuada com base em 
várias ferramentas bioinformáticas permitiu a identificação de genes 
provavelmente envolvidos na resistência a antibióticos β-lactâmicos , 
aminoglicosídeos, cloranfenicol e polimixinas. Vários determinantes genéticos 
associados a sistemas de fluxo responsáveis pela expulsão de vários 
antibióticos foram também detectados. Determinantes génicos que contribuem 
para a motilidade destes genes foram também identificados, como por exemplo 
integrases, relaxases, transposases e recombinases . 
Os resultados obtidos mostram que ambos isolados P. aeruginosa E67 e C. 
haemolyticum IR17 possuem um vasto arsenal de determinantes de resistência 
codificados no seu genoma, e que no caso do isolado de Pseudomonas, 
provavelmente contribuem para a sua sobrevivência num ecossistema 
altamente poluído. Para além disso, alguns destes genes encontram-se 
associados a estruturas móveis, o que enfatiza o contributo destas plataformas 
no desenvolvimento de fenótipos de multirresistência. 
Desta forma, este trabalho possibilitou um avanço no conhecimento global do 
resistoma destas duas espécies, reforçando o interesse em estudar isolados 
ambientais que podem conter mecanismos de resistência com relevância 
clínica.  
  
   
 
  
keywords Antibiotics, antibiotic resistance, metal resistance, Pseudomonas aeruginosa, 
co-selection, Chromobacterium haemolyticum, mobile genetic elements 
 
abstract Nowadays, antibiotic resistance is a well-acknowledged global health 
problem. The overuse and misuse of antibiotics is considered to be a serious 
threat that contributes to the appearance of clinically relevant resistant 
bacteria responsible for the increase of infected patients mortality rates. 
Furthermore, the environmental contamination with these compounds is also 
considered an enhancer factor to the increase the antibiotic resistance 
prevalence. 
The aim of this study is to analyse the resistance profile and to assess co-
selection for antibiotic and metal resistance traits in Pseudomonas and 
Chromobacterium environmental isolates using a WGS approach. To do this, 
the isolates genomes were sequenced and the species identification thereof 
was confirmed by phylogenetic analysis based on the sequence of molecular 
markers. The phenotypic characteristics observed were consistent with the 
affiliation with P. aeruginosa and C. haemolyticum.  Genome analysis using 
several bioinformatics tools allowed identifying genes probably involved in 
resistance to β-lactams, aminoglycosides, chloramphenicol and polymyxins. 
Many genetic determinants associated to efflux systems able to export a 
variety of compounds were also identified. Genetic determinants contributing 
to the motility of genes, such as integrases, relaxases, transposases and 
recombinases were identified, for instance.  
Results show that both P. aeruginosa E67 and C. haemolyticum IR17 have a 
vast arsenal of resistance determinants encoded in its genome, and in the 
case of the Pseudomonas isolate, it probably contributes to its survival in a 
highly polluted ecosystem. In addition, some of these genes are associated 
with mobile structures, which emphasizes the contribution of these platforms 
in the development of multidrug resistance phenotypes. Thus, this work 
enabled a breakthrough in the global knowledge of the resistome of these two 
species, reinforcing the interest in studying environmental isolates that may 
contain mechanisms of resistance of clinical relevance. 
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1 Antibiotics 
 
 
When in the year 1928 Alexander Fleming found by chance that a mould 
contamination of Penicillium notatum in a petri dish was responsible for the growth 
inhibition of staphylococci colonies due to the production of an antibacterial compound 
called penicillin, he never thought that 12 years later, this new discovery would 
revolutionise the practices of modern medicine by allowing the treatment of infectious 
diseases that were till then a death sentence1,2. Along with penicillin, other antibiotics such 
as sulphonamides and streptomycin were also discovered and its usage in surgical 
interventions and organ transplants would start to be a standard procedure in most hospitals 
and clinical facilities, marking the dawn of a new era in human healthcare3,4.  
The term antibiotic can be defined as a chemical substance that kills or inhibits the 
growth of microorganisms which can be produced by the microorganisms themselves as 
part of their secondary metabolism, by plants and also produced artificially5,6. Antibiotics 
that kill bacteria are termed bactericidal while antibiotics that inhibit the growth with no 
loss of cellular viability are considered bacteriostatic7.  
Synthetic antimicrobials drugs, such as sulphonamides inhibitors of folate 
metabolism, are chemicals exclusively produced artificially in the laboratory that started 
being applied first in the early 1900s with the same purpose of killing or inhibiting 
microorganisms5. Nowadays, sulphonamides are still one of the most widely used classes 
of antibiotics alongside with other artificial classes of antibiotics that have been developed 
over time such as quinolones and trimethoprim8,9. Despite the success of the naturally 
occurring antimicrobial drugs, researchers found out that they can be artificially modified 
to increase their efficiency and thus defined another class named semi-synthetic 
antibiotics3.  
Over the years, several new antibiotics have been developed through constant 
research and since the time when penicillin started to be used clinically, the rate of 
mortality caused by bacterial infections has dropped abruptly3,10. Furthermore, the field of 
application of these antibacterial compounds has expanded to other areas rather then 
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medicine such as agriculture, animal health and aquaculture, emphasising the great 
importance of antibiotics in today’s society11,12.  
 
 
1.1 Classes of antibiotics and mechanisms of action 
 
Currently, several classes of antibiotics have been recognized and described 
according to their mechanism of action (Figure 1)9. Antibiotics can have as target the cell’s 
protein synthesis, transcription, cell wall synthesis, the cytoplasmic membrane structure, 
DNA replication and folic acid metabolism5,7.  
 
 
Figure 1 Representation of the cellular structures that constitute the main targets of the major antimicrobial 
compounds5.  
 
1.1.1 Antibiotics	targeting	cell	wall	synthesis			
 
The bacterial cell wall is a rigid structure composed by layers of peptidoglycan, a 
covalently crossed-linked polymer matrix composed of peptide-linked β-(1–4)-N-acetyl 
hexosamine, which is located outside the cytoplasmic membrane and has the important 
role of conferring structural strength to the cell  and protection from osmotic lysis5,7. 
Although peptidoglycan is common to all bacterial cell wall composition, its abundance 
varies when looking at Gram-positive bacteria, which have a relatively thick layer of this 
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complex polysaccharide, and Gram-negative bacteria, which possess only a thin layer of 
peptidoglycan but have an outer-bilayer13.  
β-Lactams antibiotics are among the oldest groups of antibiotics and however, they 
remain one of the most used group of antibiotics in clinical settings14. Since the discovery 
of penicillin, other β-Lactam antibiotics have been discovered, possessing some molecular 
structure variations that characterize all the β-Lactam sub-classes (Table 1). However, all 
the antibiotics belonging to the β-Lactam family have in common one characteristic 
structural component, the β-Lactam ring5,14.  
 
Table 1 Brief description of the different β -lactam antibiotics sub-classes15–17.  
Sub-classes Description Examples 
Penicillins Short range antibiotics that can be divided in five 
categories: natural penicillins; penicillinase-
resistant penicillins, aminopenicillins, extended 
spectrum penicillins and aminopenicillin/β 
lactamase inhibitor combinations 
Penicillin G; Ampicilin; 
Amoxicillin; Ticarcillin; 
Piperacillin; 
Cephalosporins They share the same mechanism of action and 
have a similar structure of penicillins, having an 
additional atom in the side ring. These antibiotics 
are generally more resistant to β-lactamases than 
penicillins and have been grouped into 
generations according to their spectrum of activity 
 
1st Generation: 
Cefaloridin; Cefalotin 
2nd Generation: 
Cefaclor; Cefamandol 
3rd Generation: 
Ceftazidime; 
Cefotaxime 
4th Generation: 
Cefepine 
Carbapenems Broad-spectrum antibiotics used many times as 
last line agents, which differ structurally from 
penicillins and carbapenems by the absence of a 
acylamino substituent on the β-Lactam ring. 
Ertapenem; 
Imipenem; 
Meropenem 
Monobactams Aztreonam is the only monobactam available and 
structurally, it contains only the four membered 
ring of the basic β-lactam structure. 
Aztreonem 
 
All β-Lactams share a common mechanism of action, which is the binding of the 
transpeptidases known as penicillin binding proteins (PBP’s) and consequent inhibition of 
the peptidoglycan layer synthesis18. Consequently, the cell wall is debilitated and loses its 
integrity, resulting in cell lysis also due to the contribution of osmotic pressure 
differences7. 
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Glycopeptides, which include vancomycin, are another class of antibiotics that also 
affect the cell wall biosynthesis19. They inhibit the trans-glycosylation reaction by steric 
hindrance, having as molecular target the D-alanyl-D-alanine terminus of the cell wall 
peptidoglycan precursor9. It is also relevant the fact that glycopeptides are only effective 
against Gram-positive bacteria due to low permeability whilst β-Lactams can be used to 
treat Gram-negative and Gram-positive bacterial infections7.  
Still included in the cell wall biosynthesis-targeting category is fosfomycin, a 
broad-spectrum antibiotic belonging to the class of phosphonic antibiotics that inhibits 
phosphoenolpyruvate transferase, the first enzyme involved in the synthesis of 
peptidoglycan20.  
 
1.1.2 Antibiotics	targeting	protein	synthesis		
 
In order to stop cell protein synthesis, these antibiotics disrupt the translation 
process by interacting specifically with the cells ribosomes5. Since proteins play a major 
role in cell function, these drugs have broad activity spectrum and can be divided in two 
classes: the 50S inhibitors and the 30S inhibitors (Table 2)7. The majority of these 
antibiotics are medically relevant and also important research tools since they block 
specific steps of protein synthesis such as protein chain initiation and chain elongation5.  
 
Table 2 Major subclasses of antibiotics targeting cell protein synthesis, and some of the more well known 
examples, having in to account the classes that inhibit the 30S or the 50S ribosomal subunit5,7,9.  
50S inhibitors 
(These antibiotics work in general by physically 
blocking either initiation of protein translation 
or translocation of peptidyl-tRNA)  
-Macrolides (Erythromycin; Dirithromycin; 
Clarithromycin) 
-Lincosamides (Clindamycin) 
-Streptogramins (Dalfopristin) 
-Amphenicols (Chloramphenicol) 
-Oxazolidinones (Linezolid) 
30S inhibitors 
(Tetracycline’s block the access of aminoacyl-
tRNA to the ribosome while amynoglicosides 
bind the 16S rRNA component of the 30S 
ribosome subunit) 
-Tetracyclines  (Tetracyclin; Oxytetracyclin) 
-Aminoglycosides (Streptomycin; 
Gentamicin; Kanamycin; Neomycin; 
Amikacin) 
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1.1.3 Antibiotics	targeting	nucleic	acids	synthesis		
 
Currently, quinolones and ansamycins are the main antibiotic classes which 
mechanism of action affects the cell’s DNA and RNA synthesis, having a devastating 
effect on prokaryotic nucleic acid metabolism that most of the times results in bacterial cell 
death10. Fluoroquinolones such as ciprofloxacin and levofloxacin, derive from the 
quinolone nalidixic acid and like cephalosporins, can be divided in four generations 
according to their chemical structure and slight differences in the mechanism of action7. 
They interfere with DNA replication and transcription by targeting the bacterial DNA 
gyrase in Gram-negative bacteria and type IV topoisomerase in Gram-positive, preventing 
the supercoiling of DNA and thus leading to bacterial death21.  
Ansamycins such as Rifamycin and Naphthomycin, inhibit cell’s transcription by 
acting at the RNA synthesis level. These antibiotics bind with high affinity to the subunit 
of the RNA polymerase enzyme, leading to the inhibition of nascent RNA strand 
initializition7,22.  
 
1.1.4 Antibiotics	targeting	metabolic	pathways	
 
Sulfonamides were the first antimicrobial synthetic drugs to be used systematically 
and marked the beginning of the antibiotic revolution in medicine23. Their classification as 
antimetabolic drugs comes from the ability to compete with PABA (para-aminobenzoic 
acid) molecules, which are crucial in the synthesis of nucleotides required for DNA and 
RNA synthesis13. They compete for the active site of the enzyme involved in the 
production of dihydrofolic acid, resulting in a THF (tetrahydrofolic acid) production 
decrease and thus of DNA and RNA13. Of the several sulphonamides that have been 
developed so far, sulfamethoxazole is currently the most used in combination with 
trimethoprim (termed co-trimoxazole), which exerts a synergetic bacterial effect9.  
Trimethoprim is a completely synthetic drug with anti-metabolic activity that also 
interferes with nucleic acid synthesis through the inhibition of the enzyme dihydrofolate 
reductase (DHFR) by competitively binding to its active site13.  
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2 Antibiotic Resistance 
 
 
As previously stated in section 1, the discovery and introduction of antibiotics in 
the human healthcare system became one of the most important achievements of the 20th 
century24. Effectively, during the first couple of years when these drugs were used in 
medical practices, the bacterial infection diseases that were once almost a death sentence 
seemed to be a solved situation4. However, when Fleming first discovered penicillin, he 
also predicted that the misuse and overuse of antibiotics could lead to a problematic 
situation where these compounds would no longer be effective due to the appearance of 
resistant pathogenic microorganisms2. This prediction would turn out to be true, since ten 
years after the wide scale introduction of penicillin, resistance to antibiotics started to 
emerge25.  
However, the emergence of resistance occurred long before the first antibiotic was 
characterized9. In fact, it is presently known that antibiotic resistance (AR) is an ancient, 
naturally occurring phenomenon widespread in the environment and antibiotic resistance 
genes (ARG) predate our use of antibiotics26. Nonetheless, it is presently well known that 
the mishandling and misprescription of these drugs have transformed bacterial populations 
in such a way that many antibiotics have partially or entirely lost their effectiveness, 
making this a serious and growing global public health concern25,27.  
 
2.1 Bacterial resistance strategies 
 
Antimicrobial drug resistance can be defined as the ability of a microorganism to 
resist the effects of an antimicrobial agent to which it is normally susceptible5. This ability 
can be carried out by a multitude of mechanisms, being that the nature and efficiency of 
these resistance tools depend on the species and the particular antibiotic28. Thus, the main 
strategies used by bacteria for protection against the various antibiotic effects are 
enzymatic modification and degradation, efflux and alterations in the cell wall 
permeability, target modification and development of alternative resistance biochemical 
pathways9,28.  
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2.1.1 Enzymatic	inactivation	or	modification	of	the	antibiotic	
 
One of the main types of biochemical mechanisms of resistance used by bacteria is 
the enzyme-catalysed inactivation of antibiotics through structural modifications that result 
in the inability of the antibiotics to act in general28,29. These enzymes can be divided in two 
general classes: the class where β-lactamases are included, which includes enzymes that 
degrade antibiotics through hydrolytic activity and the class that include aminoglycoside-
modifying enzymes and chloramphenicol acetyltransferases, which perform chemical 
transformations19,30.  
β-lactamases are among the most well-known and clinically relevant resistance 
enzymes and they act by hydrolysing the β-Lactam ring of β-Lactam antibiotics (Figure 2), 
preventing the binding of these antibiotics to the active site of PBP’s enzymes13. 
 
Figure 2 Disruption of penicillin's β-lactam ring by the action of a β-lactamase, resulting in the antibiotic 
inactivation.13 
 
These enzymes were first discovered in the 1940’s in penicillin G-resistant isolates 
of E. coli and in the meantime hundreds of β-lactamases have been discovered and 
characterized31. In order to counter the action of these enzymes, β-lactamases inhibitors 
such as clavulanic acid, sulbactam and tazobactam, were developed and started to be used 
in combination with β-Lactam antibiotics in order to enhance their efficacy23.  
 Currently, there are two valid classifications that complement each other, one 
based on functional characteristics related to substrate and inhibitor profiles and the other 
based on molecular characteristics related to amino acid sequences14. The molecular 
classification resulted in the definition of four Ambler-classes, whereas classes A, C and D 
include the β-lactamases with serine at their active site such as AmpC, class B β-
lactamases are metallo-proteases that require zinc as a metal cofactor for their catalytic 
activity such as NMD-19. On the other hand, the functional classification divides β-
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lactamases in group 1 cephalosporinases (class C); group 2, which include broad-spectrum, 
inhibitor-resistant, extended spectrum β-lactamases (ESBL) and serine carbapenemases 
(class A and D) and finally group 3 metallo- β-lactamases (MBL) (class B)14.  
Among the class A β-lactamases, ESBL hold a particular significance since, in 
addition to their broad spectrum activity in antibiotics such as penicillins, cephalosporins 
and monobactam aztreonam, the occurrence of infections caused by ESBL-producing 
bacteria has been constantly rising and constitutes a serious threat to human health12. 
Additionally, a family of Class A carbapenemases named as K. pneumonia 
carbapenemases (KPC’s) also represent a clinical challenge due to the β-lactam resistance 
they mediate32. Carbapenem resistance as a result of KPC production was first described in 
a K. pneumoniae recovered in North Carolina in 199632 and since then twenty three KPC 
variants have been described, with KPC-2 being the most prevalent worldwide32,33. Also, 
the production of KPC enzymes has been reported in other Enterobacteriaceae and the 
corresponding genes are often associated with transposons and insertion sequences, which 
contributes to the cross-species transmission of blaKPC genes34,35. These enzymes mediate 
resistance to both carbapenems and extended-spectrum cephalosporins36, which are 
considered last line antimicrobials for human medicine, and thus constitute a threat to 
public health37. However, the organism from which KPC has originated is still unknown 
and recent research shows that blaKPC genes mobilization to plasmids and its further 
insertion in different open reading frames may be due to the action of a Tn3-based 
transposon38.  
On the other hand, the group of enzymes responsible for the inactivation of 
aminoglycosides, chloramphenicol, streptogramin, macrolides and rifampicin are 
transferases that act not by hydrolysis but through the binding of adenylyl, phosphoryl or 
acetyl groups to the periphery of the antibiotic molecule, therefore blocking the interaction 
of these drugs with their target19.  
 
2.1.2 Membrane	permeability	and	active	efflux	
 
Although all bacteria possess a cell wall that constitutes a first line of defence 
against the entry of small molecules, Gram-negative bacteria’s outer membrane confers a 
higher level of protection, rendering them impermeable to some antibiotics such as 
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penicillin G and platensimycin5,8. However, some antibiotics are able to penetrate the outer 
membrane by passive diffusion through porin proteins such as OmpF and OprD8. In order 
to restrict the antibiotic influx, some bacteria have developed a low-level resistance 
mechanism based on the infliction of modifications on the internal eyelet of porins that 
result in a slow drug entry into the cell28. 
In contrast with the low efficiency and poor specificity of antibiotics influx control, 
another resistance mechanism consisting of the active expelling of harmful agents present 
in the cell interior has been proved to have a high efficiency and is able to deal with a 
wide-range of unrelated antibiotics19. The task of active removal of antibiotics is carried 
out by membrane spanning efflux proteins that can be divided into five different families: 
the major facilitator superfamily (MFS); the ATP-binding cassette (ABC) superfamily; the 
small multidrug resistance (SMR) family; the resistance-nodulation-division (RND) 
superfamily and the multidrug and toxic compound extrusion (MATE) family (Figure 3) 23.  
 
 
Figure 3 Constitution and targeted antibiotics of the five families of efflux pumps39. 
 
The RND efflux pumps are the most well studied of all the five families due to their 
particular relevance in Gram-negative bacteria intrinsic resistance. In fact, evidence 
suggests that these pumps play a crucial role not only in the bacterial virulence that 
contributes to the multidrug resistance profile but also bacterial survival, colonization and 
biofilm formation, which are considered to be their primary physiological function40.  
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An alternative resistance mechanism has also been evoked to explain resistance 
against third generation cephalosporins in some Gram-negative bacteria that cannot 
inactivate or expel the antibiotic, recurring to the sequestration of the drug in stable 
intracellular complexes that end up neutralizing its effects28.  
2.1.3 Target	modification	and	molecular	bypass	
 
The affinity of antibiotics to their cellular targets can be altered as a result of two 
different events: point mutations that introduce amino acid substitutions in the target 
molecules or enzymatic alteration of antibiotics target41. The mutational target alteration is 
well known to be the basis of resistance to quinolones and fluoroquinolones through 
mutations in gyrA and gyrB genes that codify for DNA gyrase and also in parC and parE 
genes that codify for topoisomerase IV, causing the failure in the replication of these 
enzymes and therefore, quinolones cannot bind19. There is also the case where antibiotics 
need to be modified by bacterial enzymes to be in its active form, so mutations in the genes 
coding for these enzymes are a variation of this resistance mechanism28.  
In concern to enzymatic target alteration, a well known resistance mechanism is the 
enzymatic methylation of certain adenine residues of the 23S rRNA subunit that prevents 
antibiotics belonging to the macrolides, lincosamides, streptogramins classes to correctly 
position in the peptidyltransferase domain and consequently the protein synthesis occurs 
normally28.  
Finally, some bacteria possess a different resistance mechanism that consists in the 
production of an alternative target or metabolic pathway that is resistant to the antibiotic 
inhibitory effect and thus allows the bacteria to survive.19,29 
 
2.2 Intrinsic and acquired antibiotic resistance 
 
Bacterial AR can be achieved through intrinsic or acquired mechanisms23. Intrinsic 
resistance involves no genetic alterations and implies that the resistance mechanisms are 
naturally occurring in the genes of the host’s chromosome or plasmids, being always 
present in a given phylogenetic group30. This type of resistance is common in entire 
bacterial species and includes strategies like the resistance of all Gram-negative bacteria to 
glycopeptides due to the non permeability of the outer membrane, in Gram-negative 
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bacteria to hydrophilic antibiotics and the resistance of anaerobic bacteria to 
aminoglycosides since their movement across the cytoplasmic membrane is an oxygen–
dependent process23,28. Additionally, intrinsic resistance is not affected by the misuse of 
antibiotics and represents a major contribution to antibiotic research and the pursuit for 
specific therapies25.  
On the other hand, acquired resistance is based on microorganism’s ability to 
interchange genetic material and also chromosomal mutations19. Chromosomal mutations 
can result in reduced target affinity, alterations in regulatory networks and also reduced 
access of the antibiotic to its target28. Several of these mutation-based resistance events 
have been reported and constitute a relevant contribution to the bacteria resistance profile: 
rifampin resistance can be the consequence of point mutations on highly conserved regions 
of the rpoB gene30, synthetic drugs such as quinolones, sulphonamides and trimethoprim 
can be ineffective due to single nucleotide polymorphisms (SNPs), macrolide resistance 
can derive from nucleotide base substitutions in the 23S rRNA gene9, β-lactam antibiotics 
resistance can occur owing to chromosomal mutations that result in the overproduction of 
the AmpC β-lactamase and also efflux pumps can be overexpressed due to mutational 
events42, among other examples. However, these point mutations in specific genes 
typically only confer moderate levels of resistance to antibiotics, since sequential 
mutations must be accumulated in order to have a sufficient expression that can be 
considered clinically significant28.  
In contrast, most clinically relevant antimicrobial resistance is a result of the 
acquisition of exogenous DNA coding for resistance determinants28. This genetic material 
codes for a variety of resistance mechanisms that were referred in section 2.1 and its 
transfer can be mediated by different mobile genetic elements between organisms 
belonging to the same genus and also between evolutionary distant organisms, for instance 
Gram-positive and Gram-negative bacteria30. 
 
2.2.1 Horizontal	gene	transfer	of	resistance	genes	
 
The process by which prokaryotes acquire genes from other microbes is entitled 
Horizontal Gene Transfer (HGT) and involves a donor cell that contributes part of its 
genome and a recipient cell, which may belong to a different species from the donor13. AR 
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genes (ARG) and other determinants that confer a selective advantage to bacteria can be 
transferred horizontally between bacteria in the form of different genetic elements through 
three main mechanisms: transduction, conjugation and transformation (Figure 4) 4,19.  
 
 
Figure 4 Main strategies used by bacteria for the acquisition of AR30. 
 
Transformation can occur in both Gram-negative and Gram-positive bacteria who 
are termed “competent” and consists in the capacity to acquire free DNA from the 
environment and integrate it into its genome across regions of relative or complete 
homology through recombination processes28.  
Transduction implies the action of replication virus such as bacteriophages that 
have the capacity to transfer its DNA to spatially distant bacteria communities9.  
Conjugation is one of the most relevant mechanisms used by bacteria in the 
exchange of ARG and is performed with the involvement of physical contact between two 
bacteria mediated by structures named pili13. Although in transformation and transduction 
DNA can also be transferred in this form, in conjugation, mobile genetic elements such as 
plasmids and integrative conjugation elements are of great importance4.  
 Plasmids are autonomously replicating circular or linear segments of extra 
chromosomal DNA that contain their own origin of replication and can be found in many 
microorganisms in the Bacteria, Archaea, and Eukaryota domains43. Plasmids that own 
conjugation genes are called conjugative and generally carry complete sets of genes 
necessary for transfer9. Most of the so-called R-Plasmids are an example of these plasmids 
that encode for the exchange functions themselves and are given this designation since 
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they encode genes that confer resistance to the main classes of antibiotics, toxic metals and 
virulence determinants that contribute to bacterial survival19.  
Integrative conjugation elements are generally termed conjugative transposons and 
consist of mobile genetic segments that encode a site-specific transposase that allows them 
to move from one replicon to another within or between cells28. Transposons have been 
proved to have the ability to mediate the spread of AR and there are several classes of 
transposons based on their mechanisms of transposition, although they all have common 
features: they have palindromic sequences known as inverted repeats at each end, they 
don’t contain an origin of replication and have to be integrated into a plasmid or 
chromosome in order to be maintained9,42.  
In addition to transposons and plasmids, integrons are another example of mobile 
genetic elements that function as gene capture systems through a specific recombination 
mechanism and can be transferred both in plasmids and in transposons19. These elements 
are known for capturing and expressing gene cassettes, which can encode AR determinants 
and they all have a mutual gene coding for a site-specific tyrosine recombinase called 
integrase which can excise an integrate these gene cassettes into the integrin4.  
Genomic Islands (GI’s) can be defined as clusters of genes of probable horizontal 
origin, usually with a size higher than 8 kb, which are present in archaeal and bacterial 
genomes and who are also known to have a role in the evolution of microbial genomes 
through the means of horizontal gene transfer44,45. These mobile elements normally encode 
genes involved in notable adaptations of medical and/or environment interest such as 
virulence factors and ARG45,whose ultimate goal is to confer the carrier of GI’s a fitness 
increase and a selective advantage over other bacteria46. Also, they are frequently 
integrated adjacent to tRNA genes, have a G+C content distinct from that of the host core 
chromosome and contain components of mobile genetic elements47. 
All the previously referred mobile genetic elements that primarily reside in the host 
cell’s chromosome and also have the ability to be transferred between cells by conjugation 
are termed Integrative and conjugative elements (ICEs)48. These modular mobile genetic 
elements include conjugative transposons, integrative plasmids and other elements that are 
excise to form a circular molecule, which is then transferred by conjugation and integrated 
into the genome by site-specific recombination44. Structurally, ICEs contain a core region 
of genes that encode the function necessary for transfer between bacteria, including the 
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conjugation apparatus and integrase49. ICEs size range varies approximately from 18 kb to 
more than 500 kb and can confer various phenotypes, such as antibiotic and metal 
resistance, carbon-source utilization, symbiosis, pathogenesis, restriction modification, 
bacteriocin synthesis and biofilm formation50.  
The content of these structures reveals a concerning way in which AR and 
virulence factors can be combined and transferred49. Although ICEs are being identified in 
increasing numbers as sequenced genomes databases expand exponentially, still only a few 
of these elements are precisely characterized and delineated within sequenced bacterial 
genomes48,51,52.  
The ability of mobile genetic elements containing AR genes to spread depends on a 
range of factors including, selective pressures in the environment, host factors and 
properties of the genetic elements themselves9. Regarding specific host encoded factors, 
CRISPR Cas systems comprise bacterial adaptative immune systems that function as 
variable genetic elements53. Multiple reports have suggested that these systems may play a 
major role in controlling horizontal gene transfer events and, consequently, the dynamics 
of AR gene acquisition in some bacteria such as Enterococcus faecalis and P. 
aeruginosa54.   
3 Metal Resistance  
 
 
Metal ions and metalloids such as arsenic, zinc, mercury, silver and copper have 
been proven to have an antimicrobial effect due to their capacity to induce oxidative stress 
and to combine with sulphur atoms in molecules of cysteine, leading to the denaturation 
and/or inhibition of proteins13. In fact, antimicrobial properties of metals have been used in 
the past fourth century as a treatment for wounds and in even earlier dates as a method for 
food and water decontamination55. However, alongside with antibiotics, bacteria have 
adapted to the presence of metals through a variety of chromosomal, transposon and 
plasmid-mediated resistance systems as a result of selective pressures from metal 
containing environments56. The resistance mechanisms employed by bacteria in order to 
survive in metal contaminated environments are analogous to AR mechanisms57.  
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Table 3 Resistance mechanisms applied to both metal ions and antibiotics by prokaryotes57.  
Resistance mechanism Metal ions Antibiotics 
Reduction in permeability  As, Cu, Zn, Mn, Co, Ag Chloramphenicol, Tetracycline,  
Ciprofloxacin, β-lactams  
Drug and metal alteration As, Hg β-lactams, Chloramphenicol 
Drug and metal efflux  Cu, co, Zn, Cd, Ni, As Tetracycline, Chloramphenicol,  
β-lactams 
Alteration of cellular targets Hg, Zn, Cu  Ciprofloxacin, β-lactams,  
Trimethoprim, Rifampicin 
Drug and metal sequestration Zn, Cd, Cu Coumermycin 
 
Despite of the use of all these resistance mechanisms by bacteria to counteract 
metal derived stress, efflux systems are the most used method for dealing with metals and 
have been a continuous subject of study due to their ability to expel a wide range of 
structurally dissimilar compounds using the same mechanism58,59. 
4 Co-selection of antibiotic and metal resistance  
 
 
Recently, some studies done in the antibiotic and metal resistance area have proved 
that besides their antimicrobial action, these compounds also act as selective forces for 
bacterial evolution in a process termed co-selection where the natural susceptible bacteria 
present in a community are eliminated and only the ones that own the resistance 
mechanisms are able to survive60.  
The proliferation of AR and the co-selection process are a result of two distinct 
mechanisms: the accumulation of two or more genetic determinants on the same mobile 
genetic element through mutational or gene acquisition processes which is called co-
resistance and the presence of mutated or acquired genetic determinants that provide 
tolerance to one or more antimicrobial agents, which is termed cross-resistance60,61.  
Currently, it is commonly accepted that co-selection and the presence of metal ions 
in the environment contributes to increasing resistance mechanisms due to the localization 
of ARG in close neighbourhood on genetic mobile elements62. Besides co-selection, metals 
are also known to co-regulate genes responsible for AR and decrease antibiotic 
susceptibility63.  
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5 Propagation of antibiotic and metal resistance in the 
environment 
 
The impact on human health resultant of global spread of AR is becoming a major 
concern in our society and much progress has already been achieved in order to understand 
the complex mechanisms behind selective pressures that are imposed by antimicrobial 
compounds or other contaminants and its contribute to the maintenance and spread of 
AR57. However, most of the investigation done in the past few years on this subject has 
been restricted to clinical settings4.  
Only recently researchers are beginning to realize that some pathogenic strains of 
several bacteria genera have established environmental reservoirs of ARG that can 
ultimately be laterally transferred from environmental microorganisms to human 
commensals, posing a threat to human health12,57,64.  
Indeed, the understanding of the ecological and environmental processes involved 
in resistance gene acquisition has become a growing concern4.  
 
5.1 Impact of anthropogenic pressure in the environmental spread of ARG 
 
Besides hospitals and medical settings, AR can also be found in environmental 
settings that are subjected to the products of anthropogenic activities such as municipal and 
hospital wastewaters, pharmaceutical manufacturing effluents and aquaculture and animal 
husbandry facilities (Figure 5) 64.  
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Figure 5 Dissemination of ARG and resistance bacteria in the environment and its correlation to 
anthropogenic contamination with antibiotics65. 
 
The contribution of anthropogenic pressure to the persistence and dissemination of 
ARG and resistant bacteria is aggravated by the consequences of uncontrolled use of 
antibiotics both in human and veterinary settings, since the antibiotics can be excreted in 
an active form in both human and animals and persist in the environment, creating an 
opportunity for resistance selection within bacterial populations11,25. These activities and 
malpractices result in a continuous release of antibiotics in the environment that leads to 
the creation of resistance hotspots where antibiotics, resistant bacteria and the 
environmental bacterial flora interact and new resistant strains appear by the means of 
HGT processes4. Once present in the environment, humans may come into contact with 
resistant bacteria through various ways such as consumption of contaminated crops or 
drinking of water drawn from contaminated soils, and once when they enter our organism, 
they may be able to spread the genes that render them resistance to certain antibiotics to the 
human microbiome25,66.  
Currently, some large-scale studies are being made in order to try to understand the 
relationships between the consumption of antibiotics and the occurrence of antimicrobial 
resistance in humans and food-producing animals67. However, even with the recent 
knowledge increase regarding the reservoir of ARG in environmental landscapes and the 
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effects of anthropogenic activities, there is still a need to understand the complex 
interactions involved in AR proliferation in environmental microbial communities4,61.  
 
5.2 Multidrug-resistant bacteria: a threat to human healthcare 
 
 
Co-selection processes constitute the foundation of another relevant phenomenon 
termed multidrug-resistance (MDR), which consists in the non-susceptibility to at least one 
agent in three or more antimicrobial categories60. The continued selective pressure by 
different drugs over the years has resulted in bacteria resistant to more then one type of 
antibiotic due the possession of multiple resistance mechanisms such as novel penicillin-
binding proteins (PBP’s), enzymatic mechanisms of drug modification, mutated drug 
targets, enhanced efflux pump expression and altered membrane permeability23.  
One of the most famous cases of MDR was the appearance of methicillin-resistant 
Staphylococcus aureus (MRSA), which is resistant not only to methicillin but usually also 
to aminoglycoside, macrolides, tetracycline, chloramphenicol and lincosamides18. MRSA, 
along with MDR organisms such as Pseudomonas aeruginosa, Acinetobacter baumanii 
and extensively drug-resistant Mycobacterium tuberculosis, gave rise to infections for 
which there are almost no effective antimicrobial agents and turn out to be deadly, 
especially in developing countries that don’t have access to basic medical cares (Figure 6) 
4,30.  
 
Figure 6 Estimated deaths to AR every year by 20501. 
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Also, there is a considerable lack of data regarding the consumption of antibiotics, their 
persistence in the environment and also there is a need for the efficient monitoring of 
infections with MDR bacteria, especially in these countries1,67.  
Thus, AR, and more specifically, MDR is considered to be a growing worldwide 
problem and the international community is now starting to develop strategies to fight this 
phenomenon, since it is the source of millions of hospital infections all over the world that 
frequently end up in the patient’s death27.  
5.3 Molecular and Bioinformatic tools role in ARG screening 
 
Since the beginning of the genomic era in 1995, much progress has been achieved 
in regard to sequencing technologies which has been accompanied by a decrease in its 
monetary costs68. These technological breakthroughs led to the emergence of massive 
parallel sequencing platforms like Roche/454, Illumina and Ion Torrent, which allow the 
production of an incredible amount of data associated to entire bacterial genomes that 
exceed by far the original Sanger sequencing capacity69. To store the resulting genomic 
information, there was a need for the development of various biological databases in silico 
and bioinformatic tools that permit the access and management of massive amount of the 
generated data70. However, before being deposited in databases, the sequencing data 
generated by Next-Generation Sequencing (NGS) technologies must first be submitted to 
an assembly and annotation phase that includes standardized and well-defined steps71. 
First, the short read sequences (SRSs) produced must be assembled, using software 
programs, into contigs, which consist in sets of overlapping joined DNA segments that 
once placed in the right order form scaffolds (Figure 7) 72.  
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Figure 7 Graphic representation of the different genome assembly steps73. 
 
Then, some metric parameters are determined and analysed in order to access the 
quality of the assembly. These parameters include the assembly size and the N50 value, a 
median weighted statistic that is calculated by sorting all contigs from smallest to largest 
and determining the contig size at which 50 % off all bases in the assembly are contained 
in contig or scaffolds larger and smaller then this value72.  
Finally, the assembly is submitted to gene prediction/annotation, a computational 
process in which regions of the DNA containing coding genes are identified71. Automated 
annotation systems such as RAST (Rapid Annotation using Subsystem Technology) and 
IMG (Integrated Microbial Genomes) allow one to browse the annotated genomes, also 
supporting the use of external complementary and comparative tools to analyse them such 
as Glimmer for coding-sequence prediction, tRNA-Scan-SE and RNAmmer for RNA 
prediction, among others68. Nonetheless, automatic pipelines are prone to the introduction 
and propagation of poor annotation and errors and a manual curation step is often 
necessary to remove these74. Finally, after further processing, annotations are submitted to 
public databases such as Genbank or Embl, which give an enormous contribute to the 
globalization and exchange of scientific research knowledge64.  
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Concerning AR, NGS technologies have permitted the creation of AR databases 
like ResFinder, ARDB (antibiotic resistance database) and CARD (comprehensive 
antibiotic resistance database), which constitute excellent ARG screening tools64. In order 
to confirm the presence of ARG in a genome, there are several techniques that can be used 
such as AR phenotypic testing based on antibiograms and MIC (minimum inhibitory 
concentration) determination, targeted PCR and Sanger sequencing28,75. Eventually, 
genetic engineering procedures and proteomic analysis contribute to a more comprehensive 
and detailed understating of the bacterial AR framework, since they offer insights on the 
level of the gene expression and response to a variety of environmental influences57,76.  
6 Antibiotic Resistance in Pseudomonas aeruginosa 
 
Pseudomonas aeruginosa is a rod-shaped Gram-negative obligatory aerobic 
bacteria belonging to the family of Pseudomonadaceae and the Gamma-Proteobacteria 
class5,75. It has the ability to use many different organic compounds as carbon and energy 
source by employing Entner-Doudoroff pathway and can also thrive in conditions of partial 
oxygen depletion using alternative external electron acceptors or/and by fermentation of 
arginine or pyruvate5. This metabolic diversity is reflected by a large genome with an 
average size of 6.6 Mbp, being one of the largest amongst bacteria77. It is composed by a 
conserved core genome containing the majority of genes with housekeeping functions, 
which is common to nearly all members of the species and accessory genomic elements 
consisting of variable length stretches of DNA separated core genome elements77. 
Together, the accessory genomic elements form the accessory genome, which has a 
preponderant role in P. aeruginosa biology by conferring specific phenotypes, such as AR, 
that are advantageous under certain selective pressures78. 
P. aeruginosa can be found ubiquitously in nature, particularly in moist 
environments, and is well known for its high potential to form biofilms62. In fact, the 
versatility of this bacteria and its capacity to adapt to various environmental settings such 
as hospital wastewaters, respiratory equipment, solutions, medicines, and food products, 
makes it a remarkable opportunistic pathogen whose infections are nosocomial in nature 
and have a more abundant incidence in patients in intensive care or suffering from 
predisposing conditions such as cystic fibrosis, burn wounds and immunodeficiencies14,62.  
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By examining all the sequenced genomes deposited in the Pseudomonas Genome 
Database (http:// www.pseudomonas.com)79 and performing a global statistical analysis 
(Figure 8), we can infer that more than half of the host organisms or isolation sources are 
human patients while environmental Pseudomonas isolates represent a small part of the 
sequenced genomes. 
 
Figure 8 Distribution of all the sequenced Pseudomonas genomes present in the Pseudomonas Genome 
Database according to their isolation source and host organism. This analysis was made according to the 
database update done in 28/09/15. 
 
The increasing morbidity and mortality associated with P. aeruginosa infections 
has become a worldwide problem which is aggravated by the emergence of strains resistant 
to multiple classes of antibiotics76. Actually, only a few antibiotics are effective for 
treatment of these infections since this species is intrinsically resistant to a large number of 
antibiotics and also, under selective pressure it can acquire other resistance mechanisms 
through chromosomal mutations or HGT of resistance gene determinants14.  
In regards to resistance determinants possessed by P. aeruginosa, studies have 
shown the existence of intrinsic RND multidrug efflux pumps (e.g. mexAB-OprM) capable 
of exporting a broad range of substrates80, porin mutations (OprD) that result in lower 
outer membrane permeability34, a chromosomally encoded AmpC β-lactamase14 and also  
acquired resistance determinants such as ESBL’s (PER and OXA)35 and MBL (IMP and 
VIM)81, which, all together compromise the use of several varieties of penicillins, 
carbapenems and extended-spectrum cephalosporins62. Also, Pseudomonas is known for 
the common occurrence of spontaneous mutations that result in the overexpression of some 
of these resistance mechanisms42 and the dynamic propensity to acquire new resistance 
mechanisms from other genera such as Acinetobacter bumannii, Klesibella pneumonie and 
8%	
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Salmonella spp.62,82 Together, these resistance determinants can result in the appearance of 
MDR isolates that impose a huge limitation on the therapeutic choices available for 
treatment of Pseudomonas infections.18 
P.aeruginosa is also known to contain in its genome a large number of genomic 
islands, which are found in some strains and constitute an accessory genome that may 
account for 10 % of an individual isolates genetic material47. Many of the P. aeruginosa 
genomic islands are ICEs or are derived from such elements78. Some of the identified and 
characterized islands in P. aeruginosa are PAGI-1 (P. aeruginosa Genomic Island 1), a 49 
kb island identified in a urinary tract infection isolate47; PAGI-2 and PAGI-3, which are 
large genomic islands that were identified by sequencing of a hyper variable region in two 
different strains: a cystic fibrosis lung isolate and an environmental aquatic isolate47; and 
PAPI-1, which is representative of a large family of genomic islands derived from an 
ancestral pKLC102-like plasmid47. 
Additionally, the contributions of restriction modification systems, clusters of 
randomly interspersed palindromic repeats (CRISPR) and phage mediated acquired 
resistance in P. aeruginosa are still unkown, but the combination of these events probably 
restricts uptake and acquisition of exogenous elements83. 
7 Antibiotic Resistance in Chromobacterium haemolyticum 
 
 
Chromobacterium is a genus of gram-negative rod-shaped bacteria belonging to the family 
of Neisseriaceae and the Β-Proteobacteria class5. It includes 8 recognized species, some of 
which are considered opportunistic pathogens to humans, as for example C. violaceum and 
C. haemolyticum84–86. These two species in particular are closely related phylogenetically, 
which makes them hard to distinguish through the means of biochemical tests in cases of 
human infections86. In the Chromobacterium genus, cells are rod-shaped in morphology 
and are also facultative aerobes, growing fermentatively on sugars and aerobically on 
various carbon sources5. Furthermore, C. violaceum is the best-known Chromobacterium 
species and, like some few other Chromobacteria, it produces the purple pigment 
violacein, a water-insoluble pigment with both antimicrobial and antioxidant 
proprieties5,87.  
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Information on C. haemolyticum natural habit is scarce, although it has already been 
isolated from both environmental88–90 and clinical samples86,90,91. Like C. violaceum, it can 
be found in tropical and subtropical ecosystems, primarily in water and soil87. Only 
recently some studies have been focused in providing valuable phenotypic 
characterizations of the species, since there is still a lack of information on genotypic and 
phenotypic features as well as its diversity in the environment92,93. Also, only two full 
genomes of C. haemolyticum are available in Genbank, from the strains C. haemolyticum 
DSM19808 and C. haemolyticum T124, which emphasises the amount of genomic 
information that is still unexplored. 
Carbapenems and ciprofloxacin are, nowadays, the most frequently used drugs to combat 
infections caused by Chromobacterium spp.85,90 and also, C. haemolyticum infections 
sepsis was in some cases reversed with antibacterial therapy90.  
Detailed knowledge on C. haemolyticum resistance profile is also scarce, though some 
studies suggest that it may be more resistant to antibiotics than C. violaceum93, exhibiting 
resistance to penicillin, ceftriaxone, cefepime and ticarcillin/clavulanate90,93. This 
resistance profile may be the result of the expression of genes coding for various β-lactam, 
such as class A carbapenemases, which have been recently reported in C. haemolyticum, 
and multidrug resistance genes such as efflux pumps33,94.
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8 Scopes and objectives 
 
 
Antimicrobial resistance within a wide range of infectious agents such as bacteria, 
parasites, viruses and fungi is a growing public health problem of broad concern to 
countries, which threatens the effective prevention and treatment of a broad range of 
infections. 
The exposure of environmental settings to clinically relevant ARG and AR bacteria 
that derive from anthropogenic sources, together with the excessive use of antibiotics is 
currently considered to be a serious problem and ever-increasing evidence shows that the 
evolution and spread of AR in the environment contributes to its occurrence in clinical and 
urban settings.  
Some bacteria that belong to the Pseudomonas genus are an example of pathogens 
that can be commonly found in hospital settings and are also known for its high potential to 
develop multi-drug and metal resistance. Due to their clinical relevance, it is important to 
understand the impact of human contaminants in the co-selection for antibiotic and metal 
resistance traits in environmental Pseudomonas. Also, the sudden increase in the number 
of Chromobacterium severe infection reports, especially in tropical and subtropical 
regions, and the existent lack of knowledge regarding this genus has raised the need to 
study their AR arsenal.  
Taking this into account, the major aims of this work are: 
- to analyse the genomic resistance profile of two environmental isolates; 
- to confirm the AR traits through phenotypic tests and find evidence of co-
selection phenomenon’s; 
- to identify and characterize new significant resistance determinants;  
 
For this, the genome of environmental strains will be sequenced, annotated and   
resistance determinants of interest will be selected for detailed analysis.    
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MATERIALS AND METHODS
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1 Strain selection  
 
Pseudomonas E67 was part of a collection of bacterial isolates previously obtained 
from Halimione portulacoides95, a small metal-accumulator halophyte greyish-shrub. Plant 
samples were collected from Ria de Aveiro salt marshes, in an area contaminated with high 
levels of metals both in sediments and accumulated in H. portulacoides tissues96. The 
bacterial isolation and identification procedures were described previously95. Briefly 
isolates were cultivated on MacConkey agar plates and incubated at 37 ºC for 16 h. The 
isolate was identified at the genus level by sequencing the 16S rRNA gene.   
On the other hand, Chromobacterium IR17 was isolated from river water from 
River Alfusqueiro located in the Vouga River hydrographic basin. River water was filtered 
in sterile 0.45-µm-pore-size cellulose ester filters, and the membranes placed on 
MacConkey agar plates (Merck) supplemented with carbapenem and imipenem89. These 
antibiotics are considered last-line drugs for the treatment of serious infections caused by 
multiresistant bacteria32,89. Imipenem resistant bacteria were incubated at 37 ºC for 16h and 
colonies were then purified and stored in 20 % glycerol at -80 ºC. 
2  Optimal growth conditions 
 
The determination of the isolates optimal temperature, salinity and pH growth 
conditions was conducted. For this, isolates were grown on LA (Luria Agar) medium and 
subjected to different temperatures - 25 ºC, 30 ºC and 37 ºC  -, salt (NaCl) concentrations – 
0.5 %, 1.0 %, 2.0 %, 4.0 % and 8.0 % - and pH conditions of 4.5, 6.0, 7.0 and 8.0. Three 
replicates and four dilutions of culture with an OD600 (optical density at 600 nm) of 0,6 of 
both Pseudomonas E67 and Chromobacterium IR17 were cultured and left to grow 
overnight before results were assessed.  
During this study, Pseudomonas E67 and Chromobacterium IR17 were then 
cultivated in the optimal conditions, in Tryptic Soy Agar, LA, LB or Mueller Hinton 
media. Agar plates were stored at 4 ºC for further use. Cultures were also stored in 20 % 
glycerol at -80 ºC. 
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3 Phenotypic resistance profile  
 
Previously, the susceptibility profiles to some antibiotics (amoxicillin, 
amoxicillin/clavulanic acid, ampicillin, aztreonam, cefepime, cefotaxime, ceftazidime, 
cephalothin, ciprofloxacin, chloramphenicol, gentamicin, imipenem, meropenem, 
kanamycin, nalidixic acid, sulfamethoxazole/trimethoprim, rifampin) were obtained by the 
agar disc diffusion method and metal susceptibility testing (As, Cr, Cu, Hg, Ni, Zn) was 
evaluated for the Pseudomonas isolate95. In the present study, additional substances were 
tested using an identical methodology, namely piperacillin/tazobactam (30 µg/6 µg), 
ticarcillin (75 µg), ticarcillin/clavulanic acid (75 µg/10 µg), and tetracycline (30 µg) 
(Oxoid, United Kingdom). Briefly, the profiles were determined by the agar disc diffusion 
method on Mueller–Hinton agar, after 24 h of incubation at 37 ºC, according to the 
Clinical Laboratory Standards Institute guidelines97. Escherichia coli ATCC 25922 was 
used as quality control.  
Antibiotic susceptibility tests were also previously performed for Chromobacterium 
IR17 by the agar disc diffusion method on Mueller–Hinton agar, with antibiotics from 6 
classes (amoxicillin, amoxicillin/clavulanic acid, cefotaxime, cefepime, imipenem, 
ertapenem, aztreonam, nalidixic acid, ciprofloxacin, kanamycin, gentamicin, 
sulfamethoxazole/trimethoprim, tetracycline and chloramphenicol), following the 
EUCAST (European Committee on Antimicrobial Susceptibility Testing) guidelines98. 
Metal (loid) susceptibility testing was performed in this study by determining minimal 
inhibitory concentrations (MICs) for 4 metals(loids). MIC of each metal(loid) was 
recorded as the lowest concentration at which the isolate did not grow. For that, the culture 
optical density was first adjusted so it would fit in the interval between 0.4 and 0.6, and 
then 5 µl were inoculated, in triplicate, on Luria-Bertani (LA) medium supplemented with 
As (5, 10 and 20 mM As as Na2AsO4), Cu (2.5 and 10 mM Cu as CuSO4.5H2O), Ni (2, 5 
and 10 mM Ni as NiSO4.6H2O) and Zn (2, 5 and 10 mM Zn as ZnCl2). 
4 Whole Genome Sequencing, assembly and annotation  
 
Pseudomonas E67 and Chromobacterium IR17 genomic DNA was isolated from 
pure cultures using the Wizard Genomic DNA purification Kit (Promega, USA), following 
manufacture’s instructions. Next, the two genomes were sequenced by STAB VIDA using 
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the Ion torrent Sequencing Technology (Life Technologies, Portugal) and resulting reads 
were then subjected to a trimming process using the CLC Genomic Workbench version 
6.5, in order to remove potential vector contamination and take care of the reads with poor 
quality100. The quality of reads was determined with the FastQC program (v3.4.1.1)101. 
CLC Bio software package was then used to assemble the genomes sequence data using 
the sequencing reads of Phred quality score Q20 and higher.  
The genome drafts were annotated using the Rapid Annotation using System 
Technology (RAST)86, an automatic annotation server for microbial genomes built upon 
the framework provided by the SEED system103. The tRNA genes were predicted using the 
tRNAscan-SE 104 while rRNA genes were predicted using RNAmmer 1.2 105. A secondary 
annotation was performed using the DOE-JGI Microbial Genome Annotation Pipeline 
(MGAP v.4) 106, which allowed to refine the results obtained with the RAST annotation by 
performing a comparative analysis. 
5 Phylogenetic analysis 
 
In order to confirm the phylogenetic affiliation of the E67 isolate, the DNA 
sequences of two housekeeping genes, 16S rRNA and gyrB, were obtained from the RAST 
annotation and submitted to a phylogenetic analysis where the sequences of other 20 type 
strains included in Pseudomonas genus were also used. In case of Chromobacterium IR17, 
the 16S rRNA gene sequence was sufficient to confirm its phylogenetic affiliation by 
comparison with other 8 type strains belonging to the Chromobacterium genus. 
The phylogenetic analysis was carried out by Molecular Evolutionary Genetics 
Analysis (MEGA) software version 6.0107 and the concatenated nucleotide sequences were 
initially aligned using the ClustalW108, application which is integrated in the MEGA6 
software. Subsequently, one phylogenetic neighbour joining tree was constructed for each 
isolate, using bootstrap values for accessing reliability of the branches that were calculated 
by resampling 1000 times.  
The average nucleotide identity (ANI) value was also calculated between the 
Pseudomonas E67 draft genome obtained in this study and the available reference genome 
of P. aeruginosa PAO1 109. This method represents a reliable and robust measure of 
genetic and evolutionary relatedness between two genomes from closely related species or 
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different strains within a species that share 80-100 % ANI, since it shows strong 
correlation to DNA-DNA reassociation values and the mutation rate of the genome110,111. 
Additionally, the RAST pipeline was also used to infer the phylogenetic affiliation 
of the isolates, since it is able to generate an estimate of the thirty closest phylogenetic 
neighbours in the SEED by comparing ab initio GLIMMER3 gene-candidates with a set of 
universal proteins plus up to two hundred unduplicated proteins103. 
5.1 Multilocus Sequence Typing 
 
Multilocus Sequence Typing (MLST) is a genetic fingerprinting method based in 
the sequence analysis of a number of housekeeping genes and the identification of 
mutational differences in order to characterize strains within species.112 Thus, to determine 
the sequence type, multilocus sequence typing (MLST) of E67 was performed according to 
the protocol of Curran et al. 113 and modified by Van Mansfeld et al. 114, using  the internal 
fragments of a group of seven housekeeping genes: acsA, aroE, guaA, mutL, nuoD, ppsA 
and trpE. The complete sequences of these genes were obtained by browsing the RAST 
annotation and using the incorporated BLAST search tool. 
6 Annotation of Antibiotic and Metal Resistance Genes 
 
The genomic resistance profile of the Pseudomonas and Chromobacterium isolates 
were obtained by browsing the RAST subsystems related to virulence, disease and 
defence, and also transposable elements. In addition, IMG annotation was accessed as well 
as three additional web-based tools: Resfinder 2.124, which uses BLAST for identification 
of acquired ARG in whole-genome data, the Resistance Gene Identifier (RGI) provided by 
CARD (Comprehensive Antibiotic Resistance Database)115, the Antibiotic Resistance 
Genes Database (ARDB)116 and BLASTn in Genbank. Additionally, IslandViewer 3 45 was 
used to predict and analyze the presence of GI’s in the E67 and IR17 isolates genome 
using P. aeruginosa PAO1 and C. haemolyticum ATCC 12472 as reference genomes. This 
tool is a widely used web-based resource that can be used in the prediction and analysis of 
GI’s present in bacterial and archaeal genomes45. 
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Characterization of P. aeruginosa E67: phenotypic and 
whole genome sequence analysis 
1 Phenotypic analysis 
 
P. aeruginosa E67 optimal temperature for growth is 37 ºC and although growth 
also occurs at 30 ºC, at 25 ºC no growth is observed. The optimal pH for growth is 6.0, 
being that growth occurs at pH 7 and 8, but not at pH 4.5. Regarding the NaCl 
concentration, growth occurs in the presence of 0.5-4 % (w/v) NaCL and optimal growth is 
observed in the presence of 0.5 % (w/v) NaCl.  
Regarding the AR phenotype, isolate E67 displayed resistance or intermediate 
resistance to several antibiotics, namely amoxicillin, the combination of amoxicillin with 
clavulanic acid, ampicillin, cefotaxime, kanamycin, cefalotin, nalidixic acid, 
chloramphenicol, rifampicin, aztreonam, imipenem, meropenem and tetracycline. 
However, it was susceptible to cefepime, ceftazidime, ciprofloxacin, gentamicin, 
ticarcillin, sulphamethoxazole with trimethoprim and piperacillin with tazobactam.  
The isolates optimal growth conditions are summarized on Table 4, together with 
the previously obtained antibiotic and metal phenotypic resistance profile.  
 
Table 4 Phenotypic caracteristics of the isolate E67 
Characteristics*  
AR phenotype AMX	AMC	AMP	ATM	CTX	KF	IPM	NA	C	K	TE	SXT	
Metal(loid) resistance phenotype As Cr Cu Hg Ni  
Temperature optimum  37 °C 
pH range for growth   6 - 8 
NaCl concentration range for growth 0.5 – 4.0 % 
* AMP –ampicillin, AMX -amoxicillin, AMC –amoxicillin/clavulanic acid, ATM –aztreonam, KF –
cephalotin, CTX –cefotaxime, IPM –imipenem, C –chloramphenicol, K-kanamycin, TE –tetracycline, SXT –
sulfamethoxazole-trimethoprim, NA –nalidixic acid; 
 
P. aeruginosa has intrinsic resistance to many antimicrobial agents including most 
penicillins, narrow-spectrum cephalosporins, cefotaxime, and also other compounds such 
as tetracycline and chloramphenicol, which in part explains the isolates resistance 
phenotype obtained14,117. However, E67 was found to have intermediate resistance to 
  
40 
 
aztreonam, imipenem and meropenem, antibiotics which are considered to be clinically 
relevant antipseudomonal drugs118. 
Considering the AR phenotype obtained and contemplating the antimicrobial 
categories and agents used by the European Centre for Disease Prevention and Control to 
define MDR in Pseudomonas, we cannot infer that the isolate E67 exhibits a MDR profile 
118. However, there is no established and consensual definition for MDR and if we take 
into account both the intrinsic and acquired resistance profile, P. aeruginosa E67 can be 
considered MDR, since it exhibits resistance to more then three classes of antibiotics119. 
Also, P. aeruginosa E67 exhibits a metal(loid) resistance phenotype, including resistance 
to arsenic, chromium, copper, mercury and nickel, that allows it to survive in metal 
contaminated environments such as largo do laranjo.  
Given the relevant resistance phenotype detected, a Whole Genome Sequencing 
(WGS) approach was adopted to gain more detailed information on the P. aeruginosa E67 
antibiotic and metal resistance genetic basis, which may explain co-selection of resistance 
to both classes of compounds.  
2 Whole Genome Sequencing, assembly and annotation  
 
From the whole genome sequencing process, a total of 643.09 Mbp were generated 
comprised in 2,313,586 reads. After trimming, 2,277,184 reads were generated with an 
average length of 239,2 bp, which were then assembled de novo using CLC Genomics 
workbench software. 
From the assembly process resulted 316 contigs with a G+C content of 66.0 % and 
a N50 of 102 kb. Also based on assembly data, the estimated genome size of the isolate was 
6,876,232 bp, from which a genome coverage value of 79x was obtained, taking into 
account the average read length and the total number of reads. Sequencing and assembly 
information is summarized in Table 5. 
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Table 5 General genomic features of the whole genome sequence of P. aeruginosa E67 
Feature 
Accumulated lenght (bp) 6,876,232 
Number of Q20 bases (Mbp) 572.28 
Total number of reads 2,277,184 
Mean read length (bp) 239.23 
Number of contigs 316 
N75 (bp) 56,447 
N50 (bp) 102,009 
N25 (bp) 148,574 
Average contig length (bp) 21,830 
Average GC content 66.0 % 
Aligned reads count 2,277,184 
Number of CDS 6760 
Number of tRNA genes 62 
Number of rRNA genes 5 
 
Due to the constant and quick changes in sequencing technologies, it is difficult to 
access the quality of sequencing and assembly73. Nevertheless, there are some common 
metrics such as N50, assembly size and genome coverage that are typically used by 
researchers in order to gain insight on projects quality.72 However, when researching for 
sequencing and assembly results from other P. aeruginosa sequenced genomes, the data 
found was divergent and didn’t allow to make a comparative study with the data obtained 
on the E67 isolate.  
The RAST server predicted a total of 261 contigs containing protein coding genes 
(PEG) and 6760 coding sequences (CDS). From the annotation also resulted 563 RAST 
subsystems that covered 48.0 % of the genomic features, while 52.0 % did not belong to 
any subsystem. 
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Figure 9 Main subsystem categories resulting from RAST annotation of the P. aeruginosa E67 genome 
 
In Table 6 and Figure 9, it is noticeable that among the 563 subsystems identified, 
the main ones were related to biosynthesis and degradation of amino acids and derivatives 
followed by carbohydrates metabolism, cofactors metabolism and pigment biosynthesis.  
These results are in concordance with metabolomics studies of P. aeruginosa 
strains since metabolites related to amino acid and sugar metabolism are shown to 
represent approximately half of the bacteria metabolome.120,121 Also, the importance of 
amino acids and sugar metabolism is reflected by the broad metabolic capacity of this 
organism, rendering it able to adapt to multiple niches, many times in low nutrition 
conditions.122  
Additionally, tRNA genes were predicted using the tRNAscanSE program version 
1.21123 while rRNA genes were predicted using RNAmmer version 1.2105, which together 
detected 62  tRNA and 5 rRNA (three relative to the 5S subunit, one to the 23S subunit and 
another one relative to the 16S subunit). Also, no plasmids were found in the genome 
sequence of this bacterium. 
By comparing the sequencing and annotation results of P. aeruginosa E67 to those 
of completed Pseudomonas genomes described in literature121 and in the 
http://www.www.pseudomonas.com database, it is clear that, although variations exist 
  
43 
 
between different species and strains, the sequenced genome fits the profile of the 
Pseudomonas genus. 
 
Table 6 Functional classes of predicted genes 
Functional Class 
 
Genomic 
features 
Genes (%) 
 
Amino acids and Derivatives 
 
711 
 
8.5 
Carbohydrates 484 5.8 
Cell Division and Cell Cylce  43 0.5 
Cell Wall and Capsule 206 2.5 
Cofactors, Vitamins, Prosthetic Groups, Pigments  325 3.9 
DNA Metabolism 123 1.5 
Dormancy and Sporulation  2 0.02 
Fatty Acids, Lipids and Isoprenoids 227 2.7 
Iron acquisition and metabolism 153 1.8 
Metabolism of Aromatic Compounds 152 1.8 
Membrane Transport 271 3.2 
Miscellaneous 75 0.9 
Motility and Chemotaxis  118 1.4 
Nitrogen Metabolism  92 1.1 
Nucleosides and Nucleotides 148 1.8 
Phages, Prophages, Transposable elements, Plasmids 62 0.7 
Phosphorous Metabolism 71 0.8 
Potassium Metabolism 26 0.3 
Protein Metabolism 308 3.7 
Regulation and Cell signalling  123 1.5 
Respiration 169 2.0 
RNA Metabolism 201 2.4 
Secondary Metabolism 10 0.1 
Stress Response 200 2.4 
Sulfur Metabolism 131 1.6 
Virulence, Disease and Defence 205 2.4 
   
Hyopthetical 223 2.7 
Unknown (conserved hypothetical) 3523 42.0 
   
Total 8382 100 
 
3 Phylogenetic analysis  
 
By analysing the resulting phylogenetic tree (Figure 10), we can observe that the 
isolate E67 shares one clade cluster with P. aeruginosa DSM50071 with a bootstrap value 
of 100 %, which means the node relationship is consistent and supports the inclusion of the 
isolate in the Pseudomonas genus and the P. aeruginosa species124.  
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Figure 10 Phylogenetic tree based on 16S and gyrB sequences of 20 type strains of Pseudomonas species 
and the E67 isolate generated by the neighbour-joining method. The numbers at nodes represent levels (%) of 
bootstrap support from 1000 resampled datasets. 
 
The ANI value of 99.43 % obtained corroborates the species identification inferred 
by the analysis of the phylogenetic tree and also, using the RAST pipeline, it was possible 
to confirm the identification of the isolate as P. aeruginosa with the generation of the 
closest phylogenetic neighbours 103.  
3.1 Multilocus Sequence Typing  
 
The combination of the different alleles at each of the loci resulted in the definition 
of the ST395 by the Curran scheme for MLST113 (Table 7). This ST is commonly found in 
hospitals, urban wastewaters and wastewater treatment plants and is considered to be a 
high-risk clone due to its ability to produce ESBL such as PER-1, MBL such as IMP-29, 
various AmpC’s and aadB determinants responsible for aminoglycoside resistance, which 
makes it resistant to several different antibiotics.125 In fact, this ST is associated with a 
 P.entomophila L48
 P.putida NBRC14164
 P.protegens CHA0
 P.benzenivorans DSM8628
 P.stutzeri ATCC17588
 P.balearica SP1402
 P.azotifigens 6H33b
 P.indica IMT37
 P.mendocina CMP13540T
 P.chengduensis MBR
 P.tuomuerensis JCM14085
 P.oryzihabitans IAM1568
 P.oleovorans IAM1508
 P.composti C2
 E67
 P.aeruginosa DSM50071
 P.knackmussii B13
 P.nitroreducens NBRC12694
 P.alcaligenes ATCC14909
 P.otitidis MCC10330
 P.resinovorans NBRC106553
100
100
100
100
9 9
9 7
5 5
9 9
8 9
8 1
6 5
3 0
3 8
3 9
6 6
5 9
4 2
4 9
0.05
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MDR phenotype and has been reported in hospital wastewaters, water treatment plants and 
rivers in Hungary 126, eastern France 125, Spain 127 and also in the UK 128. However, most of 
the existing reports describing P. aeruginosa ST395 isolates refer to clinical cases 
associated to infections in cystic fibrosis patients127 and other hospital infections in the 
previously referred countries126,127,128,130.Thus, there is little information regarding the AR 
profile of ST395 isolates prevenient from environmental sceneries, which can be easily 
transferred from its natural environment to clinical settings83.  
 
Table 7 Allelic profile and subsequent ST of P. aeruginosa E67 obtained from the PubMLST database  
MLST profile   
acsA (Acetyl coenzyme A synthase) 6 
aroE (Shikimate dehydrogenase) 5 
guaA (GMP synthase) 1 
mutL (DNA mismatch repair protein) 1 
nuoD (NADH dehydrogenase I chain C,D) 1 
ppsA (Phosphoenolpyruvate synthase) 12 
trpE (Anthralite synthase component I) 1 
Sequence Type  ST395 
 
4 Antibiotic and metal resistance profile 
 
The search of P. aeruginosa E67 genome for AR determinants revealed that genes 
encoding for components of efflux pumps occupy a significant part of the isolates 
resistance arsenal, which emphasizes these pumps contribution to a reduced susceptibility 
towards antibiotics130,131. RND efflux pumps that are well characterized in this species39, 
such as MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM multidrug efflux 
systems were identified, as well as the regulator genes merR, nefxB, mexT and mexG. The 
overexpression of these pumps in P. aeruginosa is a recognized cause of antibiotic cross-
resistance, being responsible for the exportation of fluoroquinolones, tetracycline, 
chloramphenicol, some β-lactams and also other unrelated compounds involved in the 
quorum sensing process 39,62. This overexpression derives from mutations in the repressor 
genes nfxB and merR and results in an increased resistance to those antibiotics that act as 
substrates for the respective pump42.  Genes related to other efflux pumps superfamilies 
such as MFS, ABC, MATE, DMT and SMR superfamily are also well represented in the 
isolates genome and are known to play a predominant role in the resistance to certain 
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antibiotics (e.g. tetracyclines, fluoroquinolones, erythromycin and macrolides, amongst 
others) and other unrelated compounds such as organic solvents39,132,133. In fact, some 
specific components of these efflux systems were identified which confer resistance to 
specific antibiotics, namely two MFS permeases exhibiting 32.1 % and 36.5 % similarity 
with chloramphenicol efflux pump components, a MFS permease with 40.7 % similarity 
with a tetracycline efflux pump component, two ABC transporter exhibiting 32.0 % and 
29.5 % similarity with components of a Macrolide-Lincosamide-Streptogramin B efflux 
system and a membra fusion protein of the RND superfamily with 34.5 % similarity with a 
component of a macrolide-specific efflux system. We also detected a high number of genes 
coding for ABC transporter proteins that are involved in the secretion of several virulence 
factors in addition to antimicrobial compound efflux39.  
Additionally, several genes coding for components of the outer membrane porin 
OprD were identified. Although this porin’s physiological role is the transport of basic 
amino acids, it is also the main porin used by carbapenems for diffusion in P. 
aeruginosa16. However, mutations and negative regulation of the transcription of these 
genes may result in the loss of this porin and ultimately in cross-resistance to carbapenems 
like imipenem and meropenem42,119. 
Genes conferring resistance to specific antibiotics were identified and are 
summarized in Table 8. 
Resistance to β-lactam antibiotics also occupies a great portion of the isolates 
resistance arsenal. Five genes encoding for hydrolases belonging to the β-lactamase class C 
were annotated by RAST and confirmed with a second annotation based on IMG/ER. This 
is a characteristic feature described in ST395 Pseudomonas isolates125,126. One of these 
genes has high similarity 98.66 % with the chromosomal drug-inducible gene blaAmpC, 
which encodes a wide-spectrum class C β-lactamase that contributes to the intrinsic β–
lactam resistance of P. aeruginosa14. Also, directly upstream from blaAmpC, the HTH-type 
transcriptional activator AmpR was detected. When overproduced as a result of mutations, 
AmpC expression may become a major cause of resistance to widely used 
antipseudomonal penicillins (ticarcillin and piperacillin), monobactams (aztreonam), and 
third-generation (ceftazidime) and fourth-generation (cefepime) cephalosporins134. The 
other genes identified encoded putative class C β-lactamases that according to the ARDB 
database display from 27.5 % to 35.0 % similarity with previously described β-lactamases. 
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The hydrolytic pattern of these proteins has never been investigated and future studies are 
needed to assess their contribute to the pseudomonads resistance profiles. Additionally, 
gene encoding a class B β-lactamase was identified and displayed 23.4 % of similarity with 
a previously described metallo-β-lactamase. Also, a naturally occurring oxacillinase gene 
in P. aeruginosa, blaOXA-50, was detected with 99.0 % amino acid similarity with the one 
encoded in the genome of P. aeruginosa PAO1. The expression of this gene has been 
previously described to promote decreased susceptibility to ampicillin, ticarcillin, 
moxalactam and meropenem 135, though its contribution to the resistance phenotype has 
poor significance28.  
P. aeruginosa E67 resistome also harbors other relevant AR determinants such as 
genes putatively expressing phosphotransferases (24.8 % to 99.3 % similarity in terms of 
amino acid sequence with  aminoglycoside O-phosphotransferases present in P.aeruginosa 
PAO1 genome), a chloramphenicol acetyltransferase (98.7 % similarity in terms of amino 
acid sequence with a group B acetyltransferase found in the Pseudomonas genus), 
responsible for both enzymatic modification and inactivation of aminoglycosides and 
chloramphenicol respectively. These genes have been previously characterized by 
Schwartz and his co-workers in P. aeruginosa62. Also, genes were identified which 
expression may be responsible for polymyxin resistance (e.g. genes 3580 to 3583 and 
4225/4226 in contig 35 and 43, respectively) through the induction of modifications in the 
LPS structure that results in reduced binding to polymyxins136. Finally, a gene coding for a 
Virginiamycin B lyase, an enzyme responsible for the inactivation of type B streptogramin 
antibiotics137, was identified (gene 4095 in contig 42)., exhibiting 21.4 % with 
streptogramin B lyase detected in Staphylococcus cohnii.   
Additionally, a gene coding for a vancomycin B-type resistance protein was identified, 
which displayed 32.3 % similarity with a gene present in a VanG type vancomycin 
resistance operon characteristic of Enterococcus and Eubacterium138,139. This type of 
resistance in Pseudomonas is still poorly described in literature since this antibiotic is not a 
choice for treatment in cases of P. aeruginosa infections. However, the presence of this 
gene may be related to functions other than AR.  
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Table 8 Genes conferring AR found in P. aeruginosa E67 
Antibiotics 
 
Genes Contig 
location 
Products 
Aminoglycosides aph 87_6184 Aminoglycoside phosphotransferase 
 aph 92_6490 Aminoglycoside 3'-phosphotransferase type IIb 
 aph 65_5285 Predicted aminoglycoside phosphotransferase 
 aph 65_5286 Predicted aminoglycoside phosphotransferase 
Β-Lactams bla 3_2989 Β-lactamase class C and other penicillin binding proteins 
 blaOxa-50 3_3019 Β-lactamase OXA-50-like 
 bla 21_2044 Β-lactamase class C  
 bla 3_2898 Β-lactamase Class B 
 bla 48_4456 Β-lactamase class C  
 ampG 12_768 Permease 
 bla 65_5322 Β-lactamase class C  
 ampR 84_6081 HTH-type transcriptional activator ampR 
 ampC 84_6082 Β-lactamase class C  
Chloramphenicol catb4 23_2260 Type-B-Chloramphenicol  O-acetyltransferase 
 qac 3_2983 Arabinose ABC transporter permease 
 rarD 42_4113-
4114 
Chloramphenicol-sensitive protein  
 rarD 93_6551 Chloramphenicol-sensitive protein  
Lincosamide uup 91_6459 ABC transporter ATP-binding protein 
Polymyxin arnT 35_3580 Undecaprenyl phosphate-alpha-4-amino-4-deoxy-L-
arabinose arabinosyl transferase 
 arnD 35_3581 4-deoxy-4-formamido-L-arabinose-phosphoundecaprenol 
deformylase 
 arnA 35_3582 UDP-4-amino-4-deoxy-L-arabinose formylase 
 arnC 35_3583 Glycosyl transferase 
 eptA 52_4839 Phosphoethanolamine transferase 
 arnC 43_4225 Glycosyl transferase 
 arnT 43_4226 Undecaprenyl phosphate-alpha-L-Ara4N transferase 
Streptogramin  vgb1 42_4095 virginiamycin B lyase 
Tetracycline tetA 36_3666 Tetracycline resistance protein  
Vancomycin vanW 13_878 Vancomycin B-type resistance protein 
 
At least 120 β-lactamases have already been confirmed in clinical isolates of P. 
aeruginosa, and the β-lactamases coding genes found in the isolate E67 confirm the results 
of previous studies showing that this species consists of a natural reservoir of β-lactam 
resistance determinants, which compromises the use of last resource antimicrobials such as 
carboxypenicillins, ureidopenicillins, carbapenems and extended-spectrum 
cephalosporins.14,140. These results indicate that the isolate E67 is considered a MDR P. 
aeruginosa isolate, since it shows resistance to more than three classes of antibiotics119. 
Alterations in bacterial enzymes DNA gyrase and DNA topoisomerase were also checked, 
but turned out to be inexistent. 
In order to survive in an environment which in known for its high concentration of 
metals ions, P. aeruginosa E67 also harbours a vast collection of metal resistance 
determinants consisting in a total 112 PEG (Figure 12), whereas most of them code for 
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components of efflux systems. This allows the isolate to tolerate the presence of the 
arsenic, copper, mercury, chromium, cobalt, zinc, cadmium and lead.  
 
Figure 11 Distribution of the identified metal resistance PEG and other related compounds. 
 
Amongst the resistance PEG detected, genes coding for proteins present in efflux 
pumps such as as the cop system (Figure 13B) and P-type ATPase’s whose expression 
grants tolerance to metals like Copper, Zinc, Cobalt, Chromium and Cadmium are 
predominant, which confirms the importance of these systems for the survival in metal 
contaminated environments.59 Two mer operons, one complete operon located in the 
PAGI-2 genomic island (Figure 13A) and an incomplete operon missing the merA gene 
were identified. These structures are responsible for the reduction of toxic Hg2+ to volatile 
Hg0 141, and were detected in the isolates genome without the merB gene, which is a 
common feature in some organisms56. Also, mobile genetic determinants were located next 
to both operons. The ars operon (Figure 13C), which is responsible for arsenic resistance56, 
was also detected. These resistance determinants have already been identified in other 
metal resistant isolates, mainly environmental isolates that are found in agricultural soils 
irrigated with wastewater and other metal contaminated sites59,62,142. Nonetheless, these 
metal resistant isolates have also been identified in clinical settings, although the degree of 
Arsenic		7%	
Copper		31%	
Mercury		7%	Chromium		3%	
Cobalt,	Zinc	and	Cadmium	46%	
Ammonium	compounds	3%	 Tellurium		3%	
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resistance is considerably lower comparatively to environmental isolates143. Full details of 
AR traits are available in Table 8 and supplementary Table S1.  
Regarding mobile genetic elements, we explored the RAST subsystem related 
transposable elements and phage elements and we detected fourteen genes coding for 
integrases, and twenty one for transposases, as well as eleven genes coding for site-specific 
recombinases, four for relaxases and five for other widespread colonization island factors. 
In order to understand if detected mobile genetic elements are organized in specific 
chromosomal regions, we screened the E67 isolates genome for genomic islands (Figure 
12).  
 
Figure 12 Graphical map of the P. aeruginosa E67 draft genome were genomic islands are shown in red. 
G+C content plot and GC skew (purple: negative values, olive: positive values) are also shown. 
 
This analysis revealed that one of the mer operons (13A), a cop operon (13B), two 
chromate transport proteins and a ars operon (Figure 13C) are located in the mobile 
structure PAGI-278.  
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Figure 13 (A) Diagram of the mer operon present in the PAGI-2. Some genes which are not present in the 
majority of the mer operons, namely, merC, merG, merB, merD and merE, were not detected144. 
Additionally, a gene coding a Tn3 transposase was found adjacent to the operon. (B) Diagram of the cop 
operon characteristic of Pseudomonas sp. This ATPase efflux mechanism is responsible for the periplasmic 
binding of Cu(II). The HP stands for hypothetical protein and the copG was also found in the operon. (C) Ars 
operon schematic representation. It is composed by an arsenical resistance operon repressor ArsR, an arsenic 
efflux pump protein arsB coding gene, an arsenic reductase (arsC) coding gene and the arsenic resistance 
protein arsH coding gene. 
 
Also, various genes coding for proteins associated with multidrug-resistance efflux 
pumps such as membrane fusion proteins and membrane transporters belonging to the 
RND family were also identified in this mobile structure. 
Other full-length or nearly full-length genomic islands previously described in P. 
aeruginosa were also identified, namely PAGI-1, PAGI-3, PAGI-4, PAGI-6, PAGI-7, 
PAGI-8 and PAGI-947,78. Most of these structures comprise genes related to virulence, 
metabolic and transport functions44. Also, PAGI-1 and PAGI-4 are amongst the better 
characterized P. aeruginosa genomic islands related to pathogenicity, having been 
examined in greater detail in clinical isolates, while the incidence of these islands in 
environmental isolates hasn’t been given the same attention145.  
Various integrative conjugative elements (ICE’s) resembling the ones present in the 
PFGI-1 genomic island described in P. fluorescens Pf-5 were detected mainly in a PAPI-
1/PAGI-5-like genomic island and also in PAGI-2146. Some of these ICE’s belonging to 
the PFGI-1 genomic island are known to contribute to the survival of Pseudomonas 
isolates by providing protection from environmental stresses49. A genomic island 
containing CRISPR repeat sequences belonging to the I-E CRISPR-Cas subtype was also 
detected (Figure 14). Besides their well known function as a bacterial adaptative immune 
  
52 
 
system, CRISPR systems have also been proved to play an important role in controlling 
horizontal gene transfer and, consequently, the dynamics of AR in P. aeruginosa53.  
 
 
Figure 14 Schematic representation of the CRISPR-Cas type I-E structure identified in the genome of 
P.aeruginosa E67. This structure is however incomplete, missing the flanking genes cas3 and cse1 in the 
downstream region and cas1 in the upstream region. 
 
These genomic islands are known to contribute for the evolution of microbial 
genomes, conferring rapid changes in virulence potential and influencing traits such as AR, 
symbiosis, fitness and adaptation in general46. 
More information on the location and composition of the P. aeruginosa E67 
identified genomic islands is shown in Figure 12 and Table S2. 
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Characterization of C. haemolyticum IR17: phenotype and 
whole genome sequence analysis 
 
1 Phenotypic analysis 
 
C. haemolyticum IR17 showed resistance towards several β-lactams including 
penicillins (amoxicillin and amoxicillin combined with the β-lactamase inhibitor clavulanic 
acid), extended-spectrum cephalosporins (cefotaxime and cefepime) and carbapenems 
(imipenem and ertapenem)89. On the other hand it was found to be susceptible to non β-
lactams such as tetracycline, quinolones and aminoglycosides89. Also, when exposed to 
metal containing culture medium, C. haemolyticum IR17 showed low tolerance levels to 
copper, zinc, nickel and arsenic. It showed only a weak growth in medium with zinc and 
nickel concentration of 2mM, and no growth in medium containing the same concentration 
of copper and arsenic. Thus, IR17 isolate didn’t possess a significant metal resistance 
phenotype.    
Regarding the isolates optimal growth conditions, C. haemolyticum IR17 exhibited 
an optimal growth temperature of 30°C, although it also grew at 37°C but not at 25°. Also, 
the pH and the NaCl concentration range were 6-8 and 0.5-4.0%, respectively. The isolates 
phenotypic characteristics are summarized on Table 9. 
 
Table 9 Phenotypic caracteristics of the isolate IR17 
Characteristics*  
AR phenotype AMX	AMC	CTX	FEP	IPM	ETP		
Temperature optimum  30 °C 
pH range for growth   6 - 8 
NaCL concentration range for growth 0.5 – 4.0 % 
* AMX –amoxicillin, AMC -amoxicillin/clavulanic acid, CTX –cefotaxime, FEP –cefepime, IPM –
imipenem, ETP -ertapenem 
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2 General genome analysis 
 
Sequencing of C. haemolyticum IR17 genome yielded 3,088,021 paired-end 
sequence reads, which were then trimmed and assembled using CLC Genomics workbench 
version 6.5.1. (CLC Bio, Denmark). Results predicted that the draft genome of strain IR17 
contained 5,135,899 bp assembled into 421 contigs with a GC content of 62.3 %. Also, an 
average 157.8–fold genome coverage was obtained. Full sequencing details are showed in 
Table 10. 
 
Table 10 General genomic features of the whole genome sequence of C. haemolyticum IR17 
Feature 
Accumulated lenght (bp) 5,135,899  
Number of Q20 bases (Mbp) 832.06 
Total number of reads 3,088,021 
Mean read length (bp) 262,41 
Number of contigs 421 
N75 (bp) 28,088 
N50 (bp) 53,809  
N25 (bp) 80,654 
Average contig length (bp) 12,199 
Average GC content 62.3 % 
Matched reads count 3,016,599 
Number of CDS 4,797 
Number of tRNA genes 71 
Number of rRNA genes 6 
 
The genomic annotation of isolate IR17 performed by RAST included 4,797 
protein-coding sequences, distributed into 472 subsystems which cover 47.0 % of the 
genomic features, as determined by RAST (Figure 15). 
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Figure 15 Main subsystem categories resulting from RAST annotation of the C. haemolyticum IR17 genome 
 
Additionally, 71 tRNA genes and 6 rRNA genes were detected, according to 
tRNAscan-SE123 and RNAmmer105, respectively. Genomic data is summarized in Table 10.  
The subsystems which represent a more significant part of IR17 isolates gene 
repertoire are amino acids and derivatives metabolism, carbohydrates and protein 
metabolism, as showed in Table 11. 
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Table 11 Functional classes of RAST predicted genes 
Functional Class 
 
Genomic 
features 
Genes (%) 
 
Amino acids and Derivatives 
 
515 8.7 
Carbohydrates 412 6.9 
Cell Division and Cell Cycle  25 0.4 
Cell Wall and Capsule 150 2.5 
Cofactors, Vitamins, Prosthetic Groups, Pigments  251 4.2 
DNA Metabolism 103 1.7 
Dormancy and Sporulation  1 0.02 
Fatty Acids, Lipids and Isoprenoids 138 2.3 
Iron acquisition and metabolism 35 0.6 
Metabolism of Aromatic Compounds 57 1.0 
Membrane Transport 158 2.7 
Miscellaneous 44 0.7 
Motility and Chemotaxis  180 3.0 
Nitrogen Metabolism  56 0.9 
Nucleosides and Nucleotides 105 1.8 
Phages, Prophages, Transposable elements, Plasmids 50 0.8 
Phosphorous Metabolism 44 0.7 
Potassium Metabolism 25 0.4 
Protein Metabolism 264 4.4 
Regulation and Cell signalling  98 1.6 
Respiration 130 2.2 
RNA Metabolism 128 2.2 
Secondary Metabolism 6 0.1 
Stress Response 159 2.7 
Sulfur Metabolism 37 0.6 
Virulence, Disease and Defence 91 1.5 
   
Hypothetical 111 1.9 
Unknown (conserved hypothetical) 2576 43.3 
   
Total 5949 100.0 
 
3 Phylogenetic analysis 
 
The analysis of 16S rDNA gene sequence sequences and the resulting phylogenetic 
tree (Figure 16) confirmed the phylogenetic affiliation of strain IR17 to C. haemolyticum 
and comparison of genome sequences in the RAST server showed that the closest 
neighbour of C. haemolyticum IR17 was C. violaceum ATCC 12472, taking into account 
that this C. violaceum strain is the only Chromobacterium genus representative deposited 
in the SEED database. 
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Figure 16 Phylogenetic tree based on 16S sequence of type strains of Chromobacterium spp. including the 
two C. haemolyticum strains full genome sequence is available and C. haemolyticum IR17. The numbers at 
the nodes represent levels (%) of bootstrap support from 1000 resampled datasets. 
 
 
The resulting phylogenetic tree exhibits a significant statistical separation between C. 
haemolyticum and C. violaceum, which indicates that, as also proposed by Harmon et. 
Al147, 16S rRNA sequencing is an adequate method to separate these pathogenic species in 
infection cases where conventional biochemical techniques may lead to their 
misidentification147. 
4 Antibiotic resistance profile 
 
By analysing the RAST data regarding the virulence, disease and defence subsystem, it 
was possible to identify the isolates resistance arsenal and identify specific genes related to 
AR (Table 12).  
Genetic determinants encoding resistance to β-lactams were identified as for 
example, class A, class C and class D β-lactamases determinants. The complete genetic 
determinants encoding resistance to β-lactams include, two class A, two class C and one 
class D β-lactamases determinants. The class D β-lactamase is a oxacillinase with 277 
aminoacids (aa) that shows 42.7 % of similarity with a blaoxa-9 found in species belonging 
to the Pseudomonas, Klebsiella and Enterobacter genus; the class C β-lactamases are both 
cephalosporinases with 388aa and 319aa that exhibit 33.6 % and 50.3 % of similarity two 
AmpC’s characteristic of the Aeromonas and Serratia genus, respectively.  
 C.violaceum ATCC12472
 C.pseudoviolaceum LMG3953
 C.subtsugae PRAA41
 C.vaccinii MWU205
 C.piscinae LMG3947
 C.aquaticum CCSEYA1
 C.haemolyticum DSM 19808
 Chromobacterium IR17
 C.haemolyticum T124
 C.fluviatile M22511
100
9 6
6 1
100
7 5
100
7 9
0.01
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Table 12 Genes conferring AR found in C. haemolyticum IR17 
 
Antibiotics 
 
Genes Contig location Products 
Aminoglycosides aaadk 131_637 Aminoglycoside 6-adenylyltransferase  
 aaaCA4 44_2721 Aminoglycoside 6-N-acetyltransferase 
 amrB 136_699 Multidrug resistance protein 
Beta-Lactams ampC 1_18-19 Beta-lactamase class C and other penicillin 
binding proteins 
 ampC 18_1192 Class C Beta-lactamase  
 ampH 18_1193 Penicillin-binding protein 
 ampG 58_3372 Permease 
 blaOxa 24_1644 Beta-lactamase class D 
 blaKPC-like 57_3301 Class A Beta-lactamase  
 penP 73_3893 Class A Beta-lactamase  
Chloramphenicol mdfA 11_221 Multidrug translocase  
 mdfA 61_3507 Multidrug translocase  
 rarD 114_402 Chloramphenicol-sensitive protein  
Fosfomycin fosA 36_2308 Fosfomycin resistance protein 
Lincosamide uup 59_3421 ABC transporter ATP-binding protein 
 ABC transporter 
gene 
113_343 Glutathione-regulated potassium-efflux system 
ATP-binding protein 
Polymyxin arnT 126_569 Undecaprenyl phosphate-alpha-4-amino-4-
deoxy-L-arabinose arabinosyl transferase 
 arnD 126_570 4-deoxy-4-formamido-L-arabinose-
phosphoundecaprenol deformylase 
 arnA 126_571 UDP-4-amino-4-deoxy-L-arabinose formylase 
 arnC 126_572 Glycosyl transferase 
 eptA 126_575 Phosphoethanolamine transferase 
 arnC 17_1332 Glycosyl transferase 
 arnT 17_1133 Undecaprenyl phosphate-alpha-L-Ara4N 
transferase 
Fosmidomycin  fsR 58_3357-3358 Fosmidomycin resistance protein 
Fusaric acid  11_209 Hypothetical protein 
 fusE 181_1260 Fusaric acid resistance  protein  
 fusB/fusC 181_1262 Fusaric acid resistance  protein  
 fusB/fusC 186_1962 Fusaric acid resistance protein fusB/fusC 
 
Finally, the two class A β-lactamases are composed by 290aa and 295aa, the first 
one having 69.4 % of amino acid similarity with the KPC family and the second 50,4 % 
with the penP enzymes family. 
These features are likely to have a significant role in the isolates resistance towards 
β-lactam antibiotics and the presence of a chromosomal gene coding for a class A 
carbapenemase with high resemblance to KPC justified a profounder examination through 
the means of a phylogenetic analysis. MEGA6 was also used to conduct a phylogenetic 
analysis of class-A β-lactamase coded by C. haemolyticum IR17 that showed a high 
similarity with KPC-type enzymes. To do this, the sequences of the closest KPC-2 
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homologues and three Chromobacterium β-lactamases described by Poirel et al. where 
used33. 
 
  
Figure 17 Phylogenetic tree based on class A β-lactamases deduced amino acid sequence detected in C. 
haemolyticum IR17 genome (marked with a shape) and closest matches previously described33. GenBank 
accession numbers: CRP-1, WP_043629745.1; CRH-1, WP_043592266.1; CRS-1, WP_039755574.1; KPC-
2, AY034847; SFC-1, AY354402; BIC-1, GQ260093; NMC-A, Z21956; IMI-1, U50278; SME-1, U60295; 
GES-1, AAL82589; FTU-1, YP_513599.1; FPH-1, ZP_05249935.1; FRI-1, KT192551; and BKC-1, 
KP689347. The three was generated using the neighbor-joining method tree with 1000 bootstrap replicates. 
Bootstrap confidence is shown in %. 
 
The conducted phylogenetic analysis (Figure 17) indicated that the putative class-A 
β-lactamase from C. haemolyticum (CRH-1) and from Chromobacterium sp. C-61 (CRS-1) 
were more closely related with the KPC identified in the C. haemolyticum IR17 genome, 
exhibiting 98.0 % identity in terms of amino acid sequence with CHR-1 and 99.0 % with 
CRS-1. Both CRS-1, CRH-1 and CRH-IR, are more closely related to KPC-2 than to other 
class A carbapenemases (Figure 17). As suggested by Poirel et al.33, this suggests that 
blaKPC genes may have their origin in Chromobacterium genus. 
Also, chromosomal-encoded resistance to aminoglycosides was detected, namely 
the presence of three enzymes, one with 22.8 % similarity with an aminoglycoside O-
nucleotidylyltransferase, one with 25.7 % with a phosphotransferase and the other 
 CRS-1
 CRH-IR
 CRH-1
 CRP-1
 KPC-2
 SFC-1
 BIC-1
 SME-1
 NMC-A
 IMI-1
 FRI-1
 GES-1
 BKC-1
 FTU-1
 FPH-1100
100
9 7
5 6
100
9 9
9 4
100
8 9
9 5
9 7
5 6
0.1
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exhibiting 56.1 % similarity with a aminoglycoside N-acetyltransferase. Additionally, a 
protein was detected presenting 58.1 % amino acid similarity with the gluthanione 
transferase protein Fosa, responsible for fosfomycin resistance. Chromosomal-encoded 
resistance to fluoroquinolones was detected as a result of mutations identified in DNA 
gyrase genes (gyrA and gyrB) and topoisomerase IV subunit A and B (parC and parE) and 
also, genes related to AR mediated by multidrug efflux pumps were identified, as for 
instance components of the MATE, MFS, RND, ABC and DMT superfamilies. Some of 
these genes code for components of efflux systems that confer resistance to specific 
antibiotics. These include two MFS transporters exhibiting 68.6 % and 67.3 % similarity 
with components of a fosmidomycin efflux pump, four MFS transporters with 32.8 %, 34.0 
%, 28.5 % and 39.7 % similarity with components of a chloramphenicol efflux pump and 
two RND transporters showing 60.2 % and 46.6 % similarity with components of a 
macrolide specific efflux system. 
Through the means of a BLAST search in the NCBI database, we found all of these 
elements possess high similarity with others that were already described in other 
Chromobacterium genomes. Full details of AR traits are available in Table 12 and 
supplementary Table S3. 
 Moreover, genome analysis revealed that the genome of C. haemolyticulm IR17 
presented several gene clusters related to metals resistance, namely to copper, zinc, 
arsenic, chromium, cobalt and cadmium. However, taking into account the results 
revealing a low tolerance level to metals, these genes expression doesn’t seem to have a 
relevant role in the isolates metal resistance phenotype.  
It is important to notice that, when performing a WGS analysis, the presence of a 
determinate set of resistance genes doesn’t mean that they are necessarily expressed 
phenotypically. However, there is the potential that these genes may function as vectors by 
being transferred to another bacterial host, which may be pathogenic and may, this way, 
express the ARG and develop resistance.  
When screening the RAST subsystems related to mobile genetic elements, we 
detected a significant arsenal composed by thirteen transposases, five integrases, one 
putative resolvase and seven recombinases present in the C. haemolyticum’s IR17 genome. 
Also, we searched the IR17 isolates genome for genomic islands and found the presence of 
genes coding for multidrug resistance efflux pumps proteins and also genes coding for an 
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arsenate reductase and a aminoglycoside 6-adenyltransferase which confer resistance to 
arsenic and aminoglycosides, respectively, in these structures. 
 
 
 Figure 18 Graphical map of the C. haemolyticum IR17 draft genome, were genomic islands are shown in 
red. G+C content plot and GC skew (purple: negative values, olive: positive values) are also show 
 
Furthermore, similar to the C. violaceum ATCC 12472 and C. haemolyticum T124 
previously reported genomes, C. haemolyticum IR17 also contains the virulence-associated 
type III secretion genes cluster.  
More information on the location and composition of the C. haemolyticum 
identified genomic islands is shown in Figure 18 and Table S4. 
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CONCLUSIONS 
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The aim of this study was to analyse the resistome and mobilome of P. aeruginosa 
and C. haemolyticum environmental isolates using a WGS approach, making also a 
comparative study with the results obtained from phenotypic tests. P. aeruginosa E67 
isolate was obtained from a polluted salt marsh known to be heavily contaminated with 
metals95, while the C. haemolyticum IR17 was obtained from non polluted river water89. 
Thus, this study also aimed to find if there is a relation between the isolates resistance 
arsenal and the possible influence of the polluted environments in which these isolates 
exist. 
Regarding P. aeruginosa E67, this study led to the following conclusions: 
- MDR P. aeruginosa strains are present in metal-contaminated 
environments.  
- P. aeruginosa E67 owns a rich arsenal of resistance determinants. 
- MLST analysis of P. aeruginosa E67 showed that it fits the profile of 
ST395, a ST that is represented by high-risk clones often associated to 
MDR phenotypes. 
- Multidrug resistance efflux pumps represent the majority of the isolates 
resistance arsenal and are responsible for its resistance to several metals and 
antibiotics. 
- There is a predominance of cross-resistance mechanisms associated to the 
overexpression of multidrug efflux pumps. 
- Several genetic determinants contributing to motility were identified.  
Concerning C. haemolyticum IR17, the following conclusions were drawn: 
- C. haemolyticum IR17 is sensible to all the metals tested, namely copper, 
zinc, nickel and arsenic. 
- C. haemolyticum IR17 is sensible to most of the tested antibiotic classes.  
- Overall, metal and antibiotic resistance profile may be related to an absence 
of selective pressures in unpolluted river water. 
- Isolate IR17 is resistant to some last resource β-lactam antibiotics with great 
clinical relevance such as carbapenems.  
- 16S rRNA sequencing is an efficient method in distinguishing C. 
haemolyticum and C. violaceum isolates. Thus, in cases of infection, it can 
be used when conventional biochemical methods are inconclusive.  
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- The in silico genome analysis, revealed the presence of several β-lactamase 
coding genes in C. haemolyticum’s IR17 genome and also several efflux 
pumps. 
- The presence of a gene encoding a new class A β-lactamase with possible 
carbapenemase activity in the isolates genome was detected. It most likely 
contributes to the isolates resistance towards β-lactam antibiotics, namely 
carbapenems. Also, the sequence of this β-lactamase presents maximum 
homology with KPC-type carbapenemases.  
- The presence of a blaKPC-like in the IR17’s genome supports the recent 
argument stating that the Chromobacterium genus is involved in the 
evolution of KPC encoding genes33. 
 
Globally, the current study contributes to an expansion in the comprehension of the 
resistome owned by P. aeruginosa and C. haemolyticum. By adopting a WGS approach, 
we are also increasing the availability of genome sequences that can be used for the 
performance of comparative genomic analysis. In the case of P. aeruginosa, there is still 
few data regarding environmental isolates and concerning C. haemolyticum, there is a 
general lack of information, since only two genomes have been sequenced and are 
currently available. Also, the interest in analysing environmental isolates is reinforced with 
this study, since these microorganisms can contain resistance mechanisms with clinical 
relevance that can be transferred to pathogenic bacteria.  
Studies that apply whole-genome analysis are already proven to be an excellent 
means for deciphering the AR dynamics in environmental compartments and in the future, 
as this technology becomes integrated into the clinical setting, in conjunction with 
established susceptibility tests, antibiotic treatment will be enhanced in a more rigorous, 
rapid and appropriate manner. 
 
 
  
  
65 
 
 
 
 
 
REFERENCES 
 
  
66 
 
 
1. O’Neill, J. Antimicrobial Resistance : Tackling a crisis for the health and wealth of 
nations. Rev. Antimicrob. Resist. (2014). 
 
2. Ligon, B. L. Sir Alexander Fleming: Scottish researcher who discovered penicillin. 
Semin. Pediatr. Infect. Dis. 15, 58–64 (2004). 
 
3. Overbye, K. M. & Barrett, J. F. Antibiotics: where did we go wrong? Drug Discov. 
Today 10, 45–52 (2005). 
 
4. Berglund, B. Environmental dissemination of antibiotic resistance genes and 
correlation to anthropogenic contamination with antibiotics. Infect. Ecol. Epidemiol. 
1, 1–10 (2015). 
 
5. Madigan, M., Martinko, J., Stahl, D., Clark, D. Brock Biology of Microorganisms, 
(thirtheen edition) San Francisco: Pearson, 2012. Print 
 
6. Duka, R. & Ardelean, D. Phytoncides And Phytoalexins – Vegetal Antibiotics. J. 
Med. Arad. (Arad Med. Journal) 13, 19–25 (2010). 
 
7. Kohanski, M. A., Dwyer, D. J. & Collins, J. J. How antibiotics kill bacteria: from 
targets to networks. Nat. Rev. Microbiol. 8, 423–435 (2010). 
 
8. Jayaraman, R. Antibiotic resistance: An overview of mechanisms and a paradigm 
shift. Curr. Sci. 96, 1475–1484 (2009). 
 
9. van Hoek, A. H. a M., Mevius, D., Guerr, B., Mullany, P., Roberts, A. P. & Aarts, 
H. J. M. Acquired antibiotic resistance genes: an overview. Front. Microbiol. 2, 1–
27 (2011). 
 
10. de Souza Mendes, C. & de Souza Antunes, A. Pipeline of Known Chemical Classes 
of Antibiotics. Antibiotics 2, (2013). 
 
11. O’Neill, J. Tackling a global health crisis : initial steps. Rev. Antimicrob. Resist. 
(2015). 
 
12. Tacão, M., Correia, A. & Henriques, I. Resistance to broad-spectrum antibiotics in 
aquatic systems: Anthropogenic activities modulate the dissemination of blaCTX-M-
like genes. Appl. Environ. Microbiol. 78, 4134–4140 (2012). 
 
13. Bauman, R. W. Microbiology with Diseases by Taxonomy. (Fourth edition) USA: 
Pearson, 2013. Print. 
 
14. Zhao, W.-H. & Hu, Z.-Q. Βeta-lactamases identified in clinical isolates of 
Pseudomonas aeruginosa. Crit. Rev. Microbiol. 36, 245–258 (2010). 
15. Miller, E. L. The Penicillins: a review and update. J. Midwifery Womens. Health 47, 
426–434 (2002). 
 
  
67 
 
16. Papp-wallace, K. M., Endimiani, A., Taracila, M. A. & Bonomo, R. A. 
Carbapenems : Past , Present , and Future. 55, 4943–4960 (2011). 
 
17. Demain, A. L. & Elander, R. P. The β -lactam antibiotics : past , present , and future. 
Antonie Van Leeuwenhoek 75, 5–19 (1999). 
 
18. Nikaido, H. Multidrug resistance in bacteria. Annu. Rev. Biochem. 78, 119–146 
(2009). 
 
19. Giedraitienė, A., Vitkauskienė, A., Naginienė, R. & Pavilonis, A. Antibiotic 
resistance mechanisms of clinically important bacteria. Medicina (Kaunas). 47, 
137–46 (2011). 
 
20. Raz, R. Fosfomycin: an old—new antibiotic. Clin. Microbiol. Infect. 18, 4–7 (2012). 
 
21. Oliphant, C. M. & Green, G. M. Quinolones: A comprehensive review. Am. Fam. 
Physician 65, 455–464 (2002). 
 
22. Wehrli, W. Ansamycins. Chemistry, biosynthesis and biological activity. Top. Curr. 
Chem. 72, 21–49 (1977). 
 
23. Debabov, D. Antibiotic resistance: Origins, mechanisms, approaches to counter. 
Appl. Biochem. Microbiol. 49, 665–671 (2013). 
 
24. Zankari, E., Hasman, H., Cosetino, S., Vestergaard, M., Rasmussen, S., Lund, O., 
Aarestrup, F. M. & Larsen, M. V. Identification of acquired antimicrobial resistance 
genes. J. Antimicrob. Chemother. 67, 2640–4 (2012). 
 
25. Rosenblatt-Farrel, N. The Landscape of Antibiotic Resitance. Environ. Health 
Perspect. 117, 244–250 (2009). 
 
26. D’Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W. L, Schwarz, C., 
Froese, D., Zazula, G., Calmels, F., Debruyne, R., Golding, G. B., Poinar, H. N. & 
Wright, G. D. Antibiotic resistance is ancient. Nature 477, 457–61 (2011). 
 
27. Davies, D. S. C. & Gibbens, N. HM Government UK 5 Year Antimicrobial 
Resistance ( AMR ) Strategy 2013-2018. 1–72 (2014). 
 
28. Courvalin, P., Leclerq, R. & B.Rice, L. Antibiogram. (Third edition) Canada, ESKA 
publishing, Print 
 
29. Wright, G. D. Molecular mechanisms of antibiotic resistance. Chem. Commun. 47, 
4055 (2011). 
 
30. Alekshun, M. N. & Levy, S. B. Molecular Mechanisms of Antibacterial Multidrug 
Resistance. Cell 128, 1037–1050 (2007). 
 
31. Abraham, E. P. & Chain, E. An enzyme from bacteria able to destroy penicillin. 
  
68 
 
1940. Rev. Infect. Dis. 10, 677–678 (1940). 
 
32. Patel, G. & Bonomo, R. A. ‘ Stormy waters ahead ’: global emergence of 
carbapenemases. Front. Microbiol. 4, 1–17 (2013). 
 
33. Gudeta, D. D., Bortolaia, V., Jayol, A., Poirel, L., Nordmann, P. & Guardabassi, L. 
Chromobacterium spp . harbour Ambler class A b -lactamases showing high 
identity with KPC. J. Antimicrob. Chemother. 10–13 (2016). 
doi:10.1093/jac/dkw020 
 
34. Woodford, N., Turton, J. F. & Livermore, D. M. Multiresistant Gram-negative 
bacteria: The role of high-risk clones in the dissemination of antibiotic resistance. 
FEMS Microbiol. Rev. 35, 736–755 (2011). 
 
35. Jean, S., Lee, W., Lam, C., Hsu, C. & Chen, R. Carbapenemase-producing Gram-
negative bacteria : current epidemics , antimicrobial susceptibility and treatment 
options. Future Microbiol. 10, 407–425 (2015). 
 
36. Philippon, A., Slama, P. & Dény, P. A Structure-Based Classification of Class A Β-
Lactamases, a Broadly Diverse Family of Enzymes. Clin. Microbiol. Rev. 29, 29–57 
(2016). 
 
37. EFSA/ECDC. The European Union Summary Report on antimicrobial resistance in 
Antimicrobial resistance in zoonotic and indicator bacteria from humans, animals 
and food in the European Union in 2010. EFSA J. 10, (2012). 
 
38. Naas, T., Cuzon, G., Villegas, M., Lartigue, M., Quinn, J. P. and Nordmann, P.  
Genetic structures at the origin of acquisition of the β-lactamase blaKPC gene. 
Antimicrob. Agents Chemother. 52, 1257–1263 (2008). 
 
39. Piddock, L. J. V. Clinically Relevant Chromosomally Encoded Multidrug 
Resistance Efflux Pumps in Bacteria Clinically Relevant Chromosomally Encoded 
Multidrug Resistance Efflux Pumps in Bacteria. Clin. Microbiol. Rev. 19, 382–402 
(2006). 
 
40. Fernando, D. & Kumar, A. Resistance-Nodulation-Division Multidrug Efflux 
Pumps in Gram-Negative Bacteria: Role in Virulence. Antibiotics 2, 163–181 
(2013). 
 
41. Walsh, C. Antibiotics. Actions, Origins, Resistance. Washington, DC:  ASM. Press, 
2003. 
 
42. Henriques Normark, B. & Normark, S. Evolution and spread of antibiotic resistance. 
J. Intern. Med. 252, 91–106 (2002). 
 
43. Shintani, M., Sanchez, Z. K. & Kimbara, K. Genomics of microbial plasmids: 
classification and identification based on replication and transfer systems and host 
taxonomy. Front. Microbiol. 6, 1–16 (2015). 
  
69 
 
 
44. Dobrindt, U., Hochhut, B., Hentschel, U. & Hacker, J. Genomic Islands in 
Pathogenic and Environmental Microorganisms. 2, 414–424 (2004). 
 
45. Dhillon, B. K., Laird, M. R., Shay, J. A., Winsor, G. L., Lo, R., Nizam, F., Pereira, 
S. K., Waglechner, N., McArthur, A. G., Langille, M. G. I. & Brinkman, F. S. L.  
IslandViewer 3: more flexible, interactive genomic island discovery, visualization 
and analysis. Nucleic Acids Res. 1–5 (2015). doi:10.1093/nar/gkv401 
 
46. Hacker, J. & Carniel, E. Ecological fitness , genomic islands and bacterial 
pathogenicity. A Darwinian view of the evolution of microbes. EMBO Rep. 2, 376–
381 (2001). 
 
47. Battle, S. E., Rello, J. & Hauser, A. R. Genomic Islands of Pseudomonas 
aeruginosa. Nat. Rev. Microbiol. 290, 70–78 (2010). 
 
48. Wozniak, R. A. F. & Waldor, M. K. Integrative and conjugative elements: mosaic 
mobile genetic elements enabling dynamic lateral gene flow. Nat. Rev. Microbiol. 8, 
552–63 (2010). 
 
49. Seth-smith, H. & Croucher, N. J. Breaking the ICE. Nat. Rev. Microbiol. 7, 328–329 
(2009). 
 
50. Johnson, C. M. & Grossman, A. D. Integrative and Conjugative Elements (ICEs): 
What They Do and How They Work. Annu. Rev. Genet. 49, 577–604 (2015). 
 
51. Ambroset, C., Coluzzi, C., Guédon, G., Devignes, M., Loux, V., Lacroix, T., Payot, 
S. & Leblond-Bourget, N. New Insights into the Classification and Integration 
Specificity of Streptococcus Integrative Conjugative Elements through Extensive 
Genome Exploration. Front. Microbiol. 6, 1–21 (2016). 
 
52. Burrus, V., Pavlovic, G., Decaris, B. & Guédon, G. Conjugative transposons: The 
tip of the iceberg. Mol. Microbiol. 46, 601–610 (2002). 
 
53. van Belkum, A., Soriaga, L. B., LaFave, M. C., Akella, S., Veyrieras, J., Barbu, E. 
M., Shortridge, D., Blanc, B., Hannum, G., Zambardi, G., Miller, K., Enright, M. C., 
Mugnier, N., Brami, D., Schicklin, S., Felderman, M., Schwartz, A. S., Richardson, 
T. H., Peterson, T. C., Hubby, B. & Cady, K. C. Phylogenetic Distribution of 
CRISPR-Cas Systems in Antibiotic-Resistant Pseudomonas aeruginosa. MBio 6, 1–
13 (2015). 
 
54. Turton, J. F., Wright, L., Underwood, A., Witney, A. A., Chan, Y., Al-Shalib, A., 
Arnold, C., Doumith, M., Patel, B., Planche, T. D., Green, J., Holliman, R. & 
Woodford, N. High-resolution analysis by whole-genome sequencing of an 
international lineage (Sequence Type 111) of pseudomonas aeruginosa associated 
with metallo-carbapenemases in the United Kingdom. J. Clin. Microbiol. 53, 2622–
2631 (2015). 
 
  
70 
 
55. Reardon, S. Bacterial arms race revs up. Nature 521, 402–403 (2015). 
 
56. Bruins, M. R., Kapil, S. & Oehme, F. W. Microbial Resistance to Metals in the 
Environment. Ecotoxicol. Environ. Saf. 45, 198–207 (2000). 
 
57. Baker-Austin, C., Wright, M. S., Stepanauskas, R. & McArthur, J. V. Co-selection 
of antibiotic and metal resistance. Trends Microbiol. 14, 176–182 (2006). 
 
58. Nies, D. H. Efflux-mediated heavy metal resistance in prokaryotes. FEMS 
Microbiol. Rev. 27, 313–339 (2003). 
59. Teitzel, G. M. & Parsek, M. R. Heavy Metal Resistance of Biofilm and Planktonic 
Pseudomonas aeruginosa. Appl. Environ. Microbiol. 69, 2313–2320 (2003). 
 
60. Cantón, R. & Ruiz-Garbajosa, P. Co-resistance: An opportunity for the bacteria and 
resistance genes. Curr. Opin. Pharmacol. 11, 477–485 (2011). 
 
61. Tacão, M., Moura, A., Correia, A. & Henriques, I. Co-resistance to different classes 
of antibiotics among ESBL-producers from aquatic systems. Water Res. 48, 100–
107 (2014). 
 
62. Schwartz, T. Armant, O., Bretscneider, N., Hahn, A., Kirchen, S., Seifert, M. & 
Dõtsch, A. Whole genome and transcriptome analyses of environmental antibiotic 
sensitive and multi-resistant P seudomonas aeruginosa isolates exposed to waste 
water and tap water. Microb. Biotechnol. 8, 116–130 (2015). 
 
63. Seiler, C. & Berendonk, T. U. Heavy metal driven co-selection of antibiotic 
resistance in soil and water bodies impacted by agriculture and aquaculture. Front. 
Microbiol. 3, 1–10 (2012). 
 
64. Berendonk, T. U, Mannaia, C. M., Merlin, C., Fatta-Kassinos, D., Cytryn, E., 
Walsh, F., Bürgmann, H., Sørum, H., Norström, M., Pons, M., Kreuzinger, N., 
Huovinen, P., Stefani, S., Schwartz, T., Kisand, V., Baquero, F. & Martinez, J. L. 
Tackling antibiotic resistance: the environmental framework. Nat. Rev. Microbiol. 
1–8 (2015). doi:10.1038/nrmicro3439 
 
65. Andersson, D. I. & Hughes, D. Microbiological effects of sublethal levels of 
antibiotics. Nat. Rev. Microbiol. 12, 465–78 (2014). 
 
66. Dahl, R. Tools for Tracking Antibiotic Resitance. Environ. Health Perspect. 120, 
359–361 (2012). 
 
67. ECDC, EFSA & EMA. ECDC / EFSA / EMA first joint report on the integrated 
analysis of the consumption of antimicrobial agents and occurrence of antimicrobial 
resistance in bacteria from humans and food-producing animals 1 Joint Interagency 
Antimicrobial Consumption and Resi. EFSA J. 13, 1–114 (2015). 
 
68. Loman, N. J., Constantinidou, C., Chan, J. Z. M., Halachev, M., Sergeant, M., Penn, 
C. W., Robinson, E. R. & Pallen, M. J.  High-throughput bacterial genome 
  
71 
 
sequencing: an embarrassment of choice, a world of opportunity. Nat. Rev. 
Microbiol. 10, 599–606 (2012). 
 
69. Mardis, E. R. A decade’s perspective on DNA sequencing technology. Nature 470, 
198–203 (2011). 
 
70. Stein, L. D. Integrating biological databases. Nat. Rev. Genet. 4, 337–45 (2003). 
 
71. Kisand, V. & Lettieri, T. Genome sequencing of bacteria: sequencing, de novo 
assembly and rapid analysis using open source tools. BMC Genomics 14, 211 
(2013). 
 
72. Haridas, S., Breuill, C., Bohlmann, J. & Hsiang, T. A biologist’s guide to de novo 
genome assembly using next-generation sequence data: A test with fungal genomes. 
J. Microbiol. Methods 86, 368–375 (2011). 
 
73. Baker, M. De novo genome assembly: what every biologist should know. Nat. 
Methods 9, 333–337 (2012). 
 
74. Richardson, E. J. & Watson, M. The automatic annotation of bacterial genomes. 
Brief. Bioinform. 14, 1–12 (2013). 
 
75. Schwartz, T., Volkmann, H., Kirchen, S., Kohnen, W., Schön-Hölz, Jansen, B. & 
Obst, U. Real-time PCR detection of Pseudomonas aeruginosa in clinical and 
municipal wastewater and genotyping of the ciprofloxacin-resistant isolates. FEMS 
Microbiol. Ecol. 57, 158–167 (2006). 
 
76. Nouwens, A. S., Cordwell, S. J., Larsen, M. R., Molloy, M. P., Gillings, M., 
Willcox, M. D. P. & Walsh, B. J. Complementing genomics with proteomics: The 
membrane subproteome of pseudomonas aeruginosa PAO1. Electrophoresis 21, 
3797–3809 (2000). 
 
77. Ozer, E. A., Allen, J. P. & Hauser, A. R. Characterization of the core and accessory 
genomes of Pseudomonas aeruginosa using bioinformatic tools Spine and AGEnt. 
BMC Genomics 15, 737 (2014). 
 
78. Kung, V. L., Ozer, E. A. & Hauser, A. R. The Accessory Genome of Pseudomonas 
aeruginosa. 74, 621–641 (2010). 
 
79. Winsor, G. L., Lam, D. K. W., Feming, L., Lo, R., Whiteside, M. D, Yu, N. Y., 
Hancock, R. E. W. & Brinkman, F. S. L.Pseudomonas Genome Database: Improved 
comparative analysis and population genomics capability for Pseudomonas 
genomes. Nucleic Acids Res. 39, 1–5 (2011). 
 
80. Nikaido, H. & Pagès, J. M. Broad-specificity efflux pumps and their role in 
multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. 36, 340–363 
(2012). 
 
  
72 
 
81. Zhao, W. & Hu, Z. Acquired metallo- β -lactamases and their genetic association 
with class 1 integrons and IS CR elements in Gram-negative bacteria. 10, 873–887 
(2015). 
 
82. Odumosu, B. T., Adeniyi, B. a & Chandra, R. Analysis of integrons and associated 
gene cassettes in clinical isolates of multidrug resistant Pseudomonas aeruginosa 
from Southwest Nigeria. Ann. Clin. Microbiol. Antimicrob. 12, 29 (2013). 
 
83. Kos, V. N., Déraspe, M., McLaughlin, R. E., Whiteaker, J. D., Roy, P. H., Alm, R. 
A., Corbeil, J., Gardner, H. The resistome of Pseudomonas aeruginosa in 
relationship to phenotypic susceptibility. Antimicrob. Agents Chemother. 59, 427–
436 (2015). 
 
84. Campbell, J. I., Lan, N. P. H., Qui, P. T., Dung, L. T., Farrar, J. J., Baker, S. A 
successful antimicrobial regime for Chromobacterium violaceum induced 
bacteremia. BMC Infect. Dis. 13, 1–3 (2013). 
 
85. Yang, C. & Li, Y. Chromobacterium violaceum infection : A clinical review of an 
important but neglected infection. J. Chinese Med. Assoc. 74, 435–441 (2011). 
 
86. Okada, M., Inokuchi, R., Shinohara, K., Matsumoto, A., Ono, Y., Narita, M., Ishida, 
T., Kazuki, C., Nakajima, S. & Yahagi, N. Chromobacterium haemolyticum-
induced bacteremia in a healthy young man. BMC Infect. Dis. 13, 1–4 (2013). 
 
87. Durán, N. & Menck, C. F. M. Chromobacterium violaceum : A Review of 
Pharmacological and Industiral Perspectives. Clin. Rev. Microbiol. 27, 201–222 
(2001). 
 
88. Lima-bittencourt, C. I., Astolfi-filho, S., Chartone-, E., Santos, F. R. & Nascimento, 
A. M. A. Analysis of Chromobacterium sp. natural isolates from different Brazilian 
ecosystems. BMC Microbiol. 7, 1–9 (2007). 
 
89. Tacão, M., Correia, A. & Henriques, I. Low Prevalence of Carbapenem-Resistant 
Bacteria in River Water: Resistance is Mostly Related to Intrinsic Mechanisms. 
Microb. Drug Resist. 00, 1–10 (2015). 
 
90. Takenaka, R., Nureki, S., Ueno, T. & Shigemitsu, O. Chromobacterium 
haemolyticum Pneumonia Possibly Due to the Aspiration of Runoff Water. 
Japanese J. infectous Dis. 68, 526–529 (2015). 
 
91. Tanpowpong, P., Charoenmuang, R. & Apiwattanakul, N. First pediatric case of 
Chromobacterium haemolyticum causing proctocolitis. Pediatr. Int. 56, 615–617 
(2014). 
 
92. Costa, P. S., Barbosa, F. A. R. & Nascimento, A. M. A. Characterization of a 
Chromobacterium haemolyticum population from a natural tropical lake. Lett. Appl. 
Microbiol. 52, 642–650 (2011). 
 
  
73 
 
93. Han, X. Y., Han, F. S. & Segal, J. Chromobacterium haemolyticum sp. nov., a 
strongly haemolytic species. Int. J. Syst. Evol. Microbiol. 58, 1398–1403 (2016). 
 
94. Fantinatti-Garboggini, Fabiana Almeida, R. de et al. Drug resistance in 
Chromobacterium violaceum. Genet. Mol. Res. 3, 134–147 (2004). 
 
95. Henriques, I. Tacão, M., Leite, L., Fidalgo, C., Araújo, S., Oliveira, C. & Alves, A. 
Co-selection of antibiotic and metal ( loid ) resistance in gram-negative epiphytic 
bacteria from contaminated salt marshes. Mar. Pollut. Bull. xxx, xxx–xxx (2016). 
 
96. Fidalgo, C., Henriques, I., Rocha, J., Tacão, M. & Alves, A. Culturable endophytic 
bacteria from the salt marsh plant Halimione portulacoides : phylogenetic diversity , 
functional characterization , and influence of metal ( loid ) contamination. Environ. 
Sci. Pollut. Res. (2016). doi:10.1007/s11356-016-6208-1 
 
97. Jean B. Patel, Franklin R., J. A. & Institute, C. and L. S. Performance Standards for 
Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. 
Clin. Lab. Stand. Inst. 32, (2014). 
 
98. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 
6., 1–99 (2016). 
 
99. Henriques, I. S., Fonseca, F., Alves, A., Saavedra, M. J. & Correia, A. Occurrence 
and diversity of integrons and β-lactamase genes among ampicillin-resistant isolates 
from estuarine waters. Res. Microbiol. 157, 938–947 (2006). 
 
100. CLC bio. Tutorial - Assemble to Reference. 1–10 (2015). 
 
101. Babraham Bioinformatics. FastQC: A Quality Control tool for High Throughput 
Sequence Data. (2016). at 
<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/> 
 
102. Aziz, R. K., Bartels, D, Best, A. A., DeJongh, M., Disz, T., Edwards, R. A., 
Formsma, K., Gerdes, S., Glass, E. M., Kubal, M., Meyer, F., Olsen, G. J., Olson, 
R., Osterman, A. L., Overbeek, R. A., McNeil, L. K., Paarmann, D., Paczian, T., 
Parrello, B., Pusch, G. D., Reich, C., Stevens, R., Vassieva, O., Vonstein, V., Wilke, 
A. & Zagnitko, O.  The RAST Server: rapid annotations using subsystems 
technology. BMC Genomics 9, 75 (2008). 
 
103. Overbeek, R., Olson, R., Pusch, G. D., Olsen, G. J., Davis, J. J., Disz, T., Edwards, 
R. A., Gerdes, S., Parrello, B., Shukla, M., Vonstein, V., Wattam, A. R., Xia, F. & 
Stevens, R.  The SEED and the Rapid Annotation of microbial genomes using 
Subsystems Technology (RAST). Nucleic Acids Res. 42, D206–14 (2014). 
 
104. Schattner, P., Brooks,  a. N. & Lowe, T. M. The tRNAscan-SE, snoscan and 
snoGPS web servers for the detection of tRNAs and snoRNAs. Nucleic Acids Res. 
33, W686–W689 (2005). 
 
  
74 
 
105. Lagesen, K., Hallin, P., Rødland, E. A., Stærfeldt, H., Rognes, T. & Ussery, D. W. 
RNAmmer: consistent and rapid annotation of ribosomal RNA genes. Nucleic Acids 
Res. 35, 3100–3108 (2007). 
 
106. Huntemann, M, Ivanova, N. N., Mavromatis, K., Tripp, H. J., Paez-Espino, D., 
Palaniappan, K., Szeto, E., Pillay, M., Chen, I. A., Pati, A., Nielsen, T., Markowitz, 
V. M., & Kyrpides, N. C. The standard operating procedure of the DOE-JGI 
Microbial Genome Annotation Pipeline ( MGAP v . 4 ). Stand. Genomic Sci. 10, 1–
6 (2015). 
 
107. Tamura, K., Stecher, G., Peterson, D., Filipski,  a. & Kumar, S. MEGA6: Molecular 
Evolutionary Genetics Analysis Version 6.0. Mol. Biol. Evol. 30, 2725–2729 (2013). 
 
108. Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: improving the 
sensitivity of progressive multiple sequence alignment through sequence weighting, 
position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 
4673–4680 (1994). 
 
109. Goris, J., Konstantinidis, K. T., Klappenchbank, J. A., Coenye, T., Vandamme, P. & 
Tiedje, M. DNA – DNA hybridization values and their relationship to whole-
genome sequence similarities. 57, 81–91 (2007). 
 
110. Konstantinidis, K. T. & Tiedje, J. M. Towards a genome-based taxonomy for 
prokaryotes. J. Bacteriol. 187, 6258–6264 (2005). 
 
111. Rodriguez-r, L. M. & Konstantinidis, K. T. Bypassing Cultivation To Identify 
Bacterial Species. Microbe 9, 111–118 (2014). 
 
112. Enright, M. C. & Spratt, B. G. Multilocus sequence typing. Trends Microbiol. 7, 
482–487 (1999). 
 
113. Curran, B., Jonas, D., Grundmann, H., Pitt, T. & Dowson, C. G. Development of a 
Multilocus Sequence Typing Scheme for the Opportunistic Pathogen Pseudomonas 
aeruginosa. J. Clin. Microbiol. 42, 5644–5649 (2004). 
 
114. Mansfeld, R. Van, Willems, R., Brimicombe, R., Heijerman, H., Berkhout, F. T. 
van, Wolfs, T., Ent, C. van der & Bonten, M. Pseudomonas aeruginosa Genotype 
Prevalence in Dutch Cystic Fibrosis Patients and Age Dependency of Colonization 
by Various P . aeruginosa Sequence Types. J. Clin. Microbiol. 47, 4096–4101 
(2009). 
 
115. McArthur, A. G., Waglechner, N, Nizam, F., Yan, A., Azad, M. A., Baylay, A. J., 
Bhullar, K., Canova, M. J., Pascale, G. D., Ejim, L., Kalan, L., King, A. M., Koteva, 
K., Morar, M., Mulvey, M. R., O'Brien, J. S., Pawlowski, A. C., Piddock, L. J. V., 
Spanogiannopoulos, P., Sutherland, A. D., Tang, I., Taylor, P. L., Thaker, M., 
Wang, W., Yan, M., Yu, T. & Wright, G. D. The Comprehensive Antibiotic 
Resistance Database. Antimicrob. Agents Chemother. 57, 3348–3357 (2013). 
 
  
75 
 
116. Liu, B. & Pop, M. ARDB - Antibiotic resistance genes database. Nucleic Acids Res. 
37, 443–447 (2009). 
 
117. Lutz, J. K. & Lee, J. Prevalence and antimicrobial-resistance of pseudomonas 
aeruginosa in swimming pools and hot tubs. Int. J. Environ. Res. Public Health 8, 
554–564 (2011). 
 
118. Magiorakos, A., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. 
G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Likjequist, B., Paterson, D. 
L., Rice, L. B, Stelling, J., Struelens, M. J., Vatopoulos, Weber, J. T. & Monnet. D. 
L. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an 
international expert proposal for interim standard definitions for acquired resistance. 
Clin. Microbiol. Infect. 18, 268–281 (2012). 
 
119. Hirsch, E. B. & Tam, V. H. Impact of multidrug-resistant Pseudomonas aeruginosa 
infection on patient outcomes. Expert Rev. Pharmacoecon. Outcomes Res. 10, 1–18 
(2011). 
 
120. Frimmersdorf, E., Horatzek, S., Pelnikevich, A., Wiehlmann, L. & Schomburg, D. 
How Pseudomonas aeruginosa adapts to various environments: a metabolomic 
approach. Environ. Microbiol. 12, 1734–1747 (2010). 
 
121. Silby, M. W., Winstanley, C., Godfrey, S. A. C., Levy, S. B. & Jackson, R. W. 
Pseudomonas genomes: diverse and adaptable. FEMS Microbiol. Rev. 35, 652–680 
(2011). 
 
122. Stover, C., Pham, X., Erwin, A. & Mizoguchi, S. Complete genome sequence of 
Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406, 959–964 
(2000). 
 
123. Lowe, T. M. & Eddy, S. R. tRNAscan-SE: a program for improved detection of 
transfer RNA genes in genomic sequence. Nucleic Acids Res. 25, 955–64 (1997). 
 
124. Gadagkar, S. R., Rosenberg, M. S. & Kumar, S. Inferring species phylogenies from 
multiple genes: Concatenated sequence tree versus consensus gene tree. J. Exp. 
Zool. Part B Mol. Dev. Evol. 304B, 64–74 (2005). 
 
125. Slekovec, C., Plantin, J., Cholley, P., Thouverez, M., Talon, D., Bertrand, X. & 
Hocquet, D. Tracking Down Antibiotic-Resistant Pseudomonas aeruginosa Isolates 
in a Wastewater Network. PLoS One 7, 1–7 (2012). 
 
126. Libisch, B., Balogh, B. & Füzi, M. Identification of two multidrug-resistant 
Pseudomonas aeruginosa clonal lineages with a countrywide distribution in 
Hungary. Curr. Microbiol. 58, 111–116 (2009). 
 
127. Morosini, I., Lamas, A. & Romero, B. Population Structure and Antimicrobial 
Susceptibility of both Non- Persistent and Persistent Pseudomonas aeruginosa 
Isolates Recovered in Cystic Fibrosis Patients. J. Clin. Microbiol. 51, 1–14 (2013). 
  
76 
 
 
128. Martin, K., Baddal B., Mustafa, N., Perry, C., Underwood, A., Constantidou, C., 
Loman, N., Kenna, D. T. & Jane F. Turton Clusters of genetically similar isolates of 
Pseudomonas aeruginosa from multiple hospitals in the UK. J. Med. Microbiol. 62, 
988–1000 (2013). 
 
129. Cholley, P., Thouverez, M., Hocquet, D. & Mee-Marquet, N. van der. The majority 
of multi-drug resistant Pseudomonas aeruginosa isolates from hospitals in eastern 
France belong to a few clonal types. J. Clin. Microbiol. 49, 2578–2583 (2011). 
 
130. Tian, Z. X., Aogáin, M. M., O'Connor, H. F., Fargier, E., Mooij, M. J.,  Adams, C., 
Wang, Y. & O'Gara, F. MexT modulates virulence determinants in Pseudomonas 
aeruginosa independent of the MexEF-OprN efflux pump. Microb. Pathog. 47, 
237–241 (2009). 
 
131. He, G., Kuroda, T., Mima, T., Morita, Y. & Mizushima, T. An H + -Coupled 
Multidrug Efflux Pump , PmpM , a Member of the MATE Family of Transporters , 
from Pseudomonas aeruginosa. J. Bacteriol. 186, 262–265 (2004). 
 
132. Bambeke, F. Van, Balzi, E. & Tulkens, M. Antibiotic Efflux Pumps. Biochem. 
Pharmacol. 60, 457–470 (2000). 
 
133. Vila, J. & Martínez, J. L. Clinical Impact of the Over-Expression of Efflux Pump in 
Nonfermentative Gram-Negative Bacilli , Development of Efflux Pump Inhibitors. 
Curr. Drug Targets 9, 797–807 (2008). 
 
134. Berrazeg, M. et al. Mutations in Βeta-lactamase AmpC increase resistance of 
Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob. 
Agents Chemother. 59, 6248–6255 (2015). 
 
135. Girlich, D., Naas, T. & Nordmann, P. Biochemical Characterization of the Naturally 
Occurring Oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob. Agents 
Chemother. 48, 2043–2048 (2004). 
 
136. Olaitan, A. O., Morand, S. & Rolain, J. Mechanisms of polymyxin resistance : 
acquired and intrinsic resistance in bacteria. Front. Microbiol. 5, 1–18 (2014). 
 
137. Korczynska, M., Mukhtar, T. a, Wright, G. D. & Berghuis, A. M. Structural basis 
for streptogramin B resistance in Staphylococcus aureus by virginiamycin B lyase. 
Proc. Natl. Acad. Sci. U. S. A. 104, 10388–10393 (2007). 
 
138. Boyd, D. A. Du, T., Hizon, R., Kaplen, B, Murphy, T, Tyler, S., Brown, S., 
Jamieson, F., Weiss, K, Mulvey, M. R.VanG-type vancomycin-resistant Enterococcus 
faecalis strains isolated in Canada. Antimicrob. Agents Chemother. 50, 2217–2221 (2006). 
 
139. Courvalin, P. Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 42, 
S25–34 (2006). 
 
  
77 
 
140. Thomson, J. M. & Bonomo, R. a. The threat of antibiotic resistance in Gram-
negative pathogenic bacteria: β-lactams in peril! Curr. Opin. Microbiol. 8, 518–24 
(2005). 
141. Osborn, A. M., Bruce, K. D., Strike, P. & Ritchie, D. A. Distribution, diversity and 
evolution of the bacterial mercury. FEMS Microbiol. Ecol. 19, 239–262 (1997). 
 
142. Malik, A. & Aleem, A. Incidence of metal and antibiotic resistance in Pseudomonas 
spp. from the river water, agricultural soil irrigated with wastewater and 
groundwater. Environ. Monit. Assess. 178, 293–308 (2011). 
 
143. Deredjian, A., Colinon, C., Brothier, E., Favre-Bonté, S., Cournoyer, B. & Nazaret, 
S.  Antibiotic and metal resistance among hospital and outdoor strains of 
Pseudomonas aeruginosa. Res. Microbiol. 162, 689–700 (2011) 
 
144. Boyd, E. S. & Barkay, T. The mercury resistance operon: From an origin in a 
geothermal environment to an efficient detoxification machine. Front. Microbiol. 3, 
1–13 (2012). 
 
145. Grosso.Becerra, M., Santos-medellín, C., González-Valdez, A., Méndez, J., 
Delgado, G., Morales-Espinosa, R, Servín-González, L., Alcaraz, L. & Soberón-
Chávez, G. Pseudomonas aeruginosa clinical and environmental isolates constitute 
a single population with high phenotypic diversity. BMC Genomics 15, (2014). 
 
146. Mavrodi, D. V, Loper, J. E., Paulsen, I. T. & Thomashow, L. S. Mobile genetic 
elements in the genome of the beneficial rhizobacterium Pseudomonas fluorescens 
Pf-5. BMC Microbiol. 18, 1–18 (2009). 
 
147. Harmon, N., Mortensen, J. E., Robinette, E. & Powell, E. A. Pediatric bacteremia 
caused by Chromobacterium haemolyticum/ Chromobacterium aquaticum. Diagn. 
Microbiol. Infect. Dis. (2016). doi:10.1016/j.diagmicrobio.2016.05.021 
  
78 
 
 
  
  
79 
 
 
 
 
 
 
APPENDICE 
  
80 
 
 
 
Table S1 Drug transporter and efflux pumps found in P. aeruginosa E67 
Drug transporters Genes Contig Location Gene products 
Multiple Antibiotic 
Resistance MAR Locus 
marC 19_1680 Multiple antibiotic inner 
membrane resistance protein 
 marC 75_5951 Membrane protein 
RND family transporter opmQ 27_3489 Outer	membrane	pyoverdine	
eflux	protein	 
 tolC 33_3489 Outer membrane efflux protein 
 hlyD 27_2677 HlyD	family	membrane	fusion	protein 
 bepF 99_6672 Transporter, periplasmic 
adaptor subunit 
 bepE 99_6673 Membrane transporter protein 
MexCD-OprJ  nfxB 15_1179 Transcriptional regulator 
 mexC 15_1180 Membrane fusion protein MexC 
 mexD 15_1181 Transporter permease subunit 
 oprJ 15_1182 Outer membrane lipoprotein 
from NodT family 
 nfxB 15_1183 Transcriptional regulator 
MexXY-OprM oprM 2_1718-1719 Outer membrane protein 
 mexY 2_1720-1722 Inner membrane trasnporter 
 mexX 2_1723-1724 Membrane fusion protein 
 mexZ 2_1725 TetR family transcriptional 
regulator 
MexCD-OprJ nfxB 15_1179 Transcriptional regulator 
 mexC 15_1180 Membrane fusion protein 
 mexD 15_1181 RND transporter 
 oprJ 215_1182 Outer membrane lipoprotein 
 nfxB 15_1183 Transcriptional regulator 
MexJK-OprM mexL 10_147 Transcriptional regulator 
 mexJ 10_146 Membrane fusion protein 
 mexK 10_145 Multidrug efflux transporter  
 oprM 10_143 Outer membrane efflux protein 
MexHI-OpmD mexG 67_5565 Transmembrane protein 
 mexH 67_5566 Membrane fusion protein 
 mexI 67_5567 Transporter Protein 
 OpmD 67_5569 Outer membrane protein 
MexEF-oprN mexT 16_1283 LysR-type transcriptional 
regulator 
 mexE 16_1284 Membrane fusion protein 
 mexF 16_1285 Transporter Protein 
 oprN 16_1286 Outer membrane protein 
 mexE 122_797 Periplasmic adaptor subunit 
 mexF 122_798 Transporter protein  
 oprN 122_799 Outer membrane protein 
MexAB-oprM mexR 42_4044 Transcriptional regulator MexR 
 mexA 42_4045 MexAB-oprM family 
transporter periplasmic adaptor 
subunit 
 mexB 42_4046 MexAB-oprM family 
transporter periplasmic adaptor 
subunit 
 oprM 42_4047 Outer membrane efflux protein 
 mexB 48_4426-4427 Multidrug	efflux	transporter	 
 mexA 48_4428 Efflux	membrane	fusion	protein		
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 oprM  48_4429 Outer membrane lipoprotein 
 MexB 61_6714 Inner membrane transporter 
 MexA 61_6715-6716 Membrane fusion protein 
 nalD 74_5928 Transcription repressor 
ABC family transporter ABC permease 15_1186 ABC transporter, permease 
protein 
 ABC permease 15_1187 ABC transporter, permease 
protein 
 tolC 15_1188 Outer membrane protein  
 HlyD 15_1189 HlyD family secretion protein 
 ATPase  22_2118 ATPase components of ABC 
transporters with duplicated 
ATPase domains 
 ATPase  10_141	 ABC-type	multidrug	transport	system,	ATPase	component	
 ATPase 10_188	 ABC-type	multidrug	transport	system,	ATPase	and	permease	component	
 ABC permease 19_1653	 ABC-type	multidrug	transport	system,	permease	component	
 ABC permease 34_3542	 ABC-type	multidrug	transport	system,	permease	component	
 ABC transporter 20_1849	 ATP-binding	protein	
 ABC transporter 22_2073	 ATP-binding	componente	
 ABC transporter 249_2536	 Substrate-binding	periplasmic	component	
 ABC permease 3_2983	 Arabinose	ABC	transporter	permease	
 ABC transporter 295_2865	 Substrate-binding	periplasmic	component	of	uncharacterized	ABC	transporter	
 ABC trasnporter 28_2756	 ATP-binding/permease	fusion	ABC	transporter	
 ABC transporter 36_3685	 ATP-binding/permease	fusion	ABC	transporter	
 ccsA 10_223	 CcsA	related	protein	
 ABC permease 63_5240	 Permease	componente	of	ABC-type	dipeptide/oligopeptide/nickel	transport	systems	
 ABC transporter 65_5305	 Periplasmic	substrate	binding	protein	
  3_3065	 Hypothetical	protein	
 ABC transporter 67_5496	 ABC-type	bacteriocin/lantibiotic	exporters	
 ABC transporter 67_5553	 Binding	protein	component	
 ABC transporter 30_3133-3134	 ABC	transporter	
  49_4500-4501	 Hypothetical	protein	
 ABC transporter 84_6032 ATP-binding component 
 ABC transporter 68_6507-5610 ABC transporter 
 ABC transporter 68_5621-5623 ABC-type protéase exporter 
 ABC transporter 9_6222-6223 ABC transporter 
 ABC transporter 61_6736-6737 ABC transporter 
 ABC transporter 17_1497-1499 ABC transporter 
 ABC permease 84_6033 ABC-type antimicrobial peptide 
transport system component 
 ABC transporter 49_4556-4558 ABC transporter 
 ABC transporter 146_1132 Periplasmic component 
  63_5084 Hypothetical protein 
 ABC transporter 17_1537-1539 ABC transporter 
 ABC transporter 13_994 ATP-binding protein 
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 ABC transporter 15_1185 ATP-binding protein 
 ABC transporter 17_1512 ATP binding protein 
  63_5094 Hypothetical protein 
 ABC transporter 30_3135 ATP-binding protein 
 yvcR 49_4499 ABC transporterATP-bindin 
componente  
  24_2429 Hypothetical protein 
 ABC permease 34_3543 ABC permease 
 ABC transporter 84_6005 ATPase component 
 ABC transporter 3_2882-2883 ABC transporter 
 ABC permease 19_1654 ABC permease 
 ABC transporter 1_83-84 ABC transporter 
 ABC transporter 22_2119 ATPase component 
 msbA 33_3462 Lipid A export ATP-
binding/permease protein  
 msrA 33_3434 Peptide methionine sulfoxide 
reductase 
Macrolide resistance macB 27_2678 Macrolide transport system 
ATP-binding/permease protein 
 macA 27_2679 Pyoverdine-specific efflux 
macA-like protein 
MATE family 
trasnporter 
pmpM 24_2429 MATE family efflux transporter 
 norM 4_3952 MATE family efflux transporter 
 MATE family 43_4223 multidrug resistance protein 
Membrane components 
of tripartite multidrug  
resistance system 
 
dsbA 100_329 Disulfide bond formation 
protein 
 Tripartite multidrug 
resistance system 
protein 
3_3191 Outer membrane protein 
 Tripartite	multidrug	
resistance	system	
protein 
40_3998 Transporter protein 
 Tripartite multidrug 
resistance system 
protein 
50_4679 Outer membrane transporter 
protein 
 Tripartite multidrug 
resistance system 
protein 
50_4680-4681 Membrane	fusion	component	 
 Tripartite multidrug 
resistance system 
protein 
86_6156 Outer	membrane	protein	
 
 Tripartite multidrug 
resistance system 
protein 
211_2059 Outer	membrane	component	of	tripartite	multidrug	resistance	system 
 hlyD 86_6155 Hemolysin secretion protein D 
 tolC 15_1188 Outer membrane protein 	
 hlyD	 15_1189 HlyD family  
membrane fusion protein  
 hlyD 52_4784 putative secretion protein 
 hlyD 60_5035 Multidrug resistance efflux 
pump	
 romA 111_537 Outer membrane protein romA	
 romA 21_1889 Outer membrane protein romA 
 romA 21_1922 Outer membrane protein romA 
Drug/Metabolite 
transporter superfamily 
DMT permease 22_2099 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily 
 DMT protein  24_2428 Putative DMT superfamily 
metabolite efflux protein 
percursor 
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 DMT permease 29_2840 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily 
 DMT permease 30_3177 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 30_3194 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 31_3228 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 39_3853 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 39_3857 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 43_4207 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 46_4365 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 52_4786 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 7_5690 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 72_5857 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 9_6275 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 91_6474 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
Major facilitator 
superfamily 
MFS transporter 36_3666 Tetracycline resistance protein 
 MFS transporter  86_6154 MFS transporter 
 MFS permease 92_6511 MFS permease 
 MFS transporter  24_2380 MFS transporter 
 MFS transporter 22_2100 MFS transporter 
 MFS transporter 22_2101 MFS transporter 
 MFS permease 10_181 MFS permease 
 MFS protein 10_191 MFS protein 
 MFS permease 10_225 MFS permease 
 MFS permease 10_261 MFS permease 
 MFS permease 10_284 MFS permease 
 MFS transporter 74_5929 MFS transporter 
 MFS permease 92_4511 MFS permease 
 araC 86_6155 Transcriptional regulator 
 emrB 50_4682 Multidrug resistance protein B 
 MFS 9_6402 MFS protein 
 MFS 9_6403 MFS protein 
 MFS permease 108_390 MFS permease	
 MFS permease 128_842 MFS permease 
 MFS transporter 13_944 MFS transporter 
 MFS 14_1086 MFS protein 
 MFS permease 24_2369 MFS permease 
 MFS permease 24_2419 MFS permease 
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 MFS permease 24_2529 MFS permease 
 MFS permease 42_4082 MFS permease 
 MFS transporter 25_2540 MFS transporter 
 MFS transporter 25_2540 MFS transporter 
 MFS permease 3_3060 MFS permease 
 MFS permease 33_3420 MFS permease 
 MFS permease 33_3420 MFS permease 
 MFS permease 42_4119 MFS permease 
 MFS permease 48_4460 MFS permease 
 MFS permease 68_5579 MFS permease 
 MFS permease 68_5784 MFS permease 
 MFS permease 72_5847 MFS permease 
 MFS permease 84_6014 MFS permease 
 MFS permease 9_6262 MFS permease 
 MFS permease 9_6263 MFS permease 
 MFS permease 67_5545 MFS permease 
 MFS transporter 21_2043 MFS transporter 
 MFS permease 29_2798 MFS permease 
 MFS transporter 4_3936 MFS transporter 
 MFS transporter 84_6065 MFS transporter 
 MFS transporter 9_6264 MFS transporter 
 MFF transporter 52_4789 MFS transporter 
 MFS 21_1995 MFS protein 
 MFS transporter 63_5109 MFS transporter 
 MFS transporter 68_5605 MFS transporter 
 MFS transporter 7_5677 MFS transporter 
 MFS transporter 25_2609 MFS transporter 
 MFS transporter 3_3002 MFS transporter 
 MFS transporter 4_3967 MFS transporter 
 MFS transporter 15_1154 MFS transporter 
 MFS transporter 19_1665 MFS transporter 
 MFS transporter 5_4664 MFS transporter 
 MFS transporter 112_574 MFS transporter 
 MFS transporter 112_575 MFS transporter 
 EmrB/QacA subfamily 2_1765 Drug resistance transporter 
 EmrB/QacA subfamily 18_1564 Drug resistance transporter 
 EmrB/QacA subfamily 24_2377 Drug resistance transporter 
 EmrB/QacA subfamily 24_2380 Drug resistance transporter 
 DHA2 family 68_5584 Multidrug resistance permease 
Small Multidrug 
Resistance (SMR) 
family 
emrE 33_3470 Small multidrug resistance 
pump  
 SMR efflux pumps 52_4884 Small multidrug resistance 
family-3 protein	
 
 
Table S2 Predicted genomic islands in the genome of Pseudomonas aeruginosa E67 
E67 genomic Island annotation 
 
Predicted Island 
 
Start position 
 
End position 
 
Size (bp) 
 
Annotation 
1 118,872 132,170 13,298 Taurine dioxygenase, NADP 
transhydrogenase,  Ferric sidephore 
transport system, proton channel, 
Biopolymer transport, Malonate 
descarboxylase, Triphosphoribosyl-
dephospho-CoA synthetas and transferase; 
3 1,080,969 1,172,023 91,054 PAGI-5/PAPI-1(Contains genes with 
putative metabolic functions and a PFGI-1-
like cluster with hypothetical regulatory 
proteins) 
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4 1,480,484 1,512,877 32,393 MFS permease, Transcriptional  regulators, 
Hydrolases, Gluthanione peroxidase, 
Ribonuclease D,  Thiosulfate 
sulfurtransferase, Hypothetical proteins 
5 3,484,262 3,589,262 105,000 PAGI-2 (Transport of heavy metals and 
ions, cytochrome c biogenesis, mercury 
resistance, metabolic capacities) 
 4,616,249 4,623,604 7,355 PAGI-9 (hypothetical proteins)  
6 4,752,201 4,774,680 22,479 PAGI-7 (contains transcriptional regulator 
and is integrated in a ATP-dependent 
helicase) 
7 5,145,307 5,159,050 13,743 Isochrorismate synthase siderophore, 
Pyochelin biosynthetic protein PchC, 2,3-
dihydroxybenzoate-AMP ligase 
siderophore,  Hypothetical proteins 
8 5,504,879 5,524,775 19,896 PAGI-4 (Contains genes with putative 
metabolic functions) 
9 6,234,299 6,253,186 18,887 PAGI-8 (Predicted to encode an ATPase, a 
Zn-dependent transcriptional regulator, and 
a DotA/TraY-like protein) 
10 6,269,282 6,313,853 44,571 PAGI-6 (phage related genomic Island) 
11 6,884,676 6,908,671 23,995 PAGI-1 (contains genes potentially 
involved in oxidative stress) and CRISPR-
associated proteins) 
12 7,757,760 8,787,760 103,000 PAGI-3 (Cargo genes thought to confer 
metabolic, transport, and resistance 
capacities) 
  
Table S3 Drug transporter and efflux pumps found in C. Haemolyticum IR17 
Drug transporters Genes Contig Location Gene products 
Multiple Antibiotic 
Resistance MAR Locus 
marC 28_1780 Multiple antibiotic  resistance 
protein 
 marC 3_1900 Multiple antibiotic  resistance 
protein 
 marC 57_3310 Probable	multiple	antibiotic	
resistance	protein	 
RND family transporter  136_700 Membrane	fusion	protein	 
 cmeC 147_899 Outer membrane lipoprotein  
 cmeC 150_977 Outer membrane lipoprotein 
 cmeA 156_1019 Membrane	fusion	protein 
 cmeB 156_1020 Inner membrane trasnporter 
  186_1268 Membrane	fusion	protein	 
  72_2787 Membrane	fusion	protein		
  73_3910 HlyD	family	secretion	protein	
  24_1627 Probable membrane fusion 
protein 
 RND transporter 49_2899 RND transporter 
 cmeC 55_3184 Outer membrane lipoprotein 
 nodT 57_3302 Outer membrane lipoprotein 
  57_3305 Membrane	fusion	protein		
  24_1626 Acriflavin	resistance	protein	
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  417_2619 Acriflavin	resistance	protein	
ABC family transporter ABC permease 156_1016 ABC permease component 
 ABC permease 108_168 ABC transporter permease 
protein 
 ABC permease 11_187 Probable permease of ABC 
transporter 
 ABC transporter 15_932 Probable	ABC	transporter	ATP	
binding	protein 
  ABC transporter 156_1017 Probable	ABC	transporter	ATP	
binding	protein 
 ABC permease 186_1272	 Probable permease of ABC 
transporter	
 ABC transporter 24_1567	 ABC-transporter	protein	
 ABC transporter 29_1837	 ABC-transporter	protein	
 ABC transporter 29_1841	 ABC-transporter	protein	
 ABC transporter 34_2136-2137	 Permease of ABC transporter		
 ABC permease 41_2605	 Permease of ABC transporter	
 ABC permease 44_2658	 Permease of ABC transporter	
 ABC transporter 44_2697	 ATPase	componente	of	ABC	transporter	
 ABC transporter 55_3112	 ABC-transporter	protein	
 ABC trasnporter 61_3537-3538	 ABC-transporter	protein	
 ABC transporter 62_3549		 ABC-transporter	protein	
 ABC transporter 62_3553	 ABC-transporter	protein	
 ABC transporter 73_3898-3899	 ABC-transporter	protein	
 ABC transporter 73_3909	 ATP-binding	protein	
 ABC transporter 8_4152	 ABC-transporter	protein	
 ABC transporter 87_4472	 Hypothetical	protein	
Macrolide resistance macB 150_978 Macrolide export ATP-
binding/permease protein 
 macA 150_979 Macrolide-specific efflux 
protein 
MATE family 
trasnporter 
MATE family 93_4740 Multi antimicrobial extrusiion 
protein 
 MATE family 29_1817 multidrug resistance protein 
Membrane components 
of tripartite multidrug  
resistance system 
Tripartite multidrug 
resistance system 
protein 
181_1264 Outer membrane protein 
 Tripartite	multidrug	
resistance	system	
protein 
58_3390 Outer membrane protein 
 Tripartite multidrug 
resistance system 
protein 
58__3391 Outer membrane transporter 
protein 
Drug/Metabolite 
transporter superfamily 
DMT permease 126_574 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily 
 DMT permease  14_813 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily 
 DMT permease 14_851 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily 
 DMT permease 18_1213 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily 
 DMT permease 20_1372 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 26_1714 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
  
87 
 
 DMT permease 30_1957 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 31_2026 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 44_2737 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 46_2817 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 52_2960 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 73_3870 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
 DMT permease 92_4675-4676 Permease	of	the	drug/metabolite	transporter	(DMT)	superfamily	
Major facilitator 
superfamily 
MFS permease 141_870 MFS permease	
 MFS transporter  20_1367 Probable MFS transporter 
 MFS transporter 77_4001 MFS transporter 
 MFS transporter 58_3387 MFS transporter 
  80_4189 Multidrug resistance protein 
 MFS transporter 80_4211 Probable MFS transporter 
 MFS transporter 82_4306 Probable MFS transporter 
percursor 
 MFS transporter 92_4669 MFS transporter 
  35_2298 Multidrug	resistance	protein	D	
  80_4201 Multidrug	resistance	protein	B	
  40_2287 Probable	transport	
transmembrane	protein	
  35_2226 Probable	multidrug	resistance	
protein	
 yceL 3_1857 MFS	superfamily	export	protein	
  27_1753 Multidrug	resistance	protein	B	
Other multidrug 
resistance efflux pumps 
tetR 156_1018 Transcription repressor of 
multidrug efflux pump acrAB 
operon	
  17_1147 Probable	multidrug	resistance	
protein	
 tolC 49_2900 Type	I	secretion	outer	
membrane	protein 
 
 Table S4 Predicted genomic islands in the genome of C. Haemolyticum IR17 
IR17 genomic Island annotation 
 
Predicted Island 
 
Start position 
 
End position 
 
Size (bp) 
 
Annotation 
1 719,580 725,603 6,023 Arsenate reductase; Components of tripartite 
multidrug resistance system; Tyrosine-protein 
kinase Wzc; Capsule polysaccharide export 
protein; Putative outer membrane lipoprotein; 
2 961,884 967,309 5,425 Hypothetical proteins; 
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3 1,319,436 1,329,560 10,124 Site-specific recombinase XerC; Hypothetical 
proteins; 
4 1,822,827 1,827,030 4,370 Molybdenum ABC transporter ; Hypothetical 
proteins; 
5-8 1,962,339 2,045,042 82,703 Exoenzymes regulatory protein AepA 
percursor; Transcriptional regulator; 
Prolidase; Outer membrane usher protein; 
Sensory box histidine kinase; NERD domain 
protein Hypothetical proteins;  Permease of 
the DMT superfamily; 
9 2,352,725 2,356,925 4,200 Tyrosine recombinase XerC; Hypothetical 
proteins 
10 3,165,069 3,170,367 5,298 Collagen triple helix repeat domain; Sulfate 
and thiosulfate binding protein CysP; 
Hypothetical protein; 
11 3,341,226 3,345,656 4,430 Probable transmembrane sensor; Probable 
ABC transporter; Transcriptional regulator; 
Formiminoglutamase; Hypothetical protein; 
12 4,201,558 4,206,900 5,342 Lipid carrier; UDP-N-acetylglucosamine  
4,6.dehydratase; UDP-glucose-4-epimerase; 
UDP-N-acetylglucosamine 2-epimerase   
13 4,373,434 4,378,281 4,847 Glycosyltransferase; dTDP-glucose 4,6-
dehydratase; Hypothetical protein 
14-18 4,959,190 5,109,946 150,756 Hypothetical proteins; Putrescine transport 
system permease; Putrescine transport ATP-
binding protein PotG; Regulator of 
nucleoside diphosphate kinase; Probable 
dipeptyl aminopeptidase; Retron-type RNA-
directed DNA polymerase; Aminoglycoside 
6-adenylyltransferase 
 
